Molecule	Actions/effects	Reference

Sulfur dioxide	Possible long-term cardiac abnormality	Pishgoo et al. (15)

Cardiac and mitochondrial dysfunction (rats)	Qin et al. (1)

Increase heart susceptibility to oxidative stress	Zaky et al. (16)

Inhibits the proapoptotic effect of isopropylarterenol on myocardial tissue through a bcl-2/cytc/caspase-9/caspase-3 pathway	Jin et al. (11)

Aggravates myocardial I/R injury	Zhang et al. (17)

Sulfur dioxide	Ameliorated systemic hypertension and pulmonary hypertension prevented the development of atherosclerosis and protected against myocardial ischemia-reperfusion (I/R) injury and isoproterenol-induced myocardial injury	Huang et al. (18)

Sulfites

Sulfur mustard	Modification of the ratio prooxidant/antioxidant	Shohrati et al. (19)

Reduction of serum GSH, increase of serum malondialdehyde (MDA)

Sulfites	Deleterious effects through the mitochondrial Fe3+ cyt c-mediated ROS	Velayutham et al. (20)

Reduced the length and volume of the ventricular capillaries (rats)	Noorafshan et al. (21)

With sulfite oxidase contributes in NO signaling	Wang et al. (22)

They can affect voltage-gated sodium (Na+) channels (VGSC) in a concentration-dependent manner in isolated rat ventricular myocytes. Protective action of catechins	Wei and Meng (23)

Molecule	Actions/effects	Reference

Sulfur mustard	Modification of the ratio prooxidant/antioxidant	Shohrati et al. (19)

Reduction of serum GSH, increase of serum malondialdehyde (MDA)

Sulfites	Deleterious effects through the mitochondrial Fe3+ cyt c-mediated ROS	Velayutham et al. (20)

Reduced the length and volume of the ventricular capillaries (rats)	Noorafshan et al. (21)

With sulfite oxidase contributes in NO signaling	Wang et al. (22)

They can affect voltage-gated sodium (Na+) channels (VGSC) in a concentration-dependent manner in isolated rat ventricular myocytes. Protective action of catechins	Wei and Meng (23)


	ST use			RR/OR

Sourcea	Typeb	Exposurec	Smoking	Sex	Id.	Casesd	Estimate (95%CI)	Adjustment factorse

Case-control studies

Wynder et al. 1957 [40]

- larynx cancer	Chew	Ever	Any	M	1	NA	no associationf	none

Vincent and Marchetta 1963 [45]

- larynx cancer	Snuff	Use	Any	M	2	5	1.81 (0.33–9.97)	none

Williams and Horm 1977 [55]

- larynx cancer	ST	Ever	Any	M	3	16	2.01 (1.15–3.51)g	age, race, smok

Wynder and Stellman 1977 [56]

- larynx cancer	Chew	Ever	Any	M	4	46	1.35 (0.96–1.89)g	none

	Snuff				5	15	1.46 (0.82–2.57)g	none

	ST				6	61	1.40 (1.04–1.89)h	none

Engzell et al. 1978 [57]

- nasal cancer	Snuff	Use	Any	M	7	NA	no association	none

Brinton et al. 1984 [64]

- nasal cancer	Chew	Use	Any	M+F	8	15	0.74 (0.40–1.50)	sex

	Snuff				9	23	1.47 (0.80–2.80)

	ST				10	38	1.08 (0.68–1.70)h	none

Stockwell and Lyman 1986 [70]

- nasal cancer	ST	Ever	Any	M+F	11	1	2.93 (0.40–21.66)g	none

- larynx cancer	ST	Ever	Any	M+F	12	6	2.02 (0.84–4.86)g	none

Young et al. 1986 [71]

- larynx cancer	ST	Ever	Any	M	13	NA	no association	none

Lewin et al. 1998 [102]

- larynx cancer	Snuff	Current	Any	M	14	15	1.00 (0.50–1.90)	age, alc, res, smok

		Former			15	9	0.80 (0.40–1.70)

		Ever			16	24	0.90 (0.50–1.50)

	ST use			RR/OR

Sourcea	Typeb	Exposurec	Smoking	Sex	Id.	Casesd	Estimate (95%CI)	Adjustment factorse

	ST				6	61	1.40 (1.04–1.89)h	none

Engzell et al. 1978 [57]

- nasal cancer	Snuff	Use	Any	M	7	NA	no association	none

Brinton et al. 1984 [64]

- nasal cancer	Chew	Use	Any	M+F	8	15	0.74 (0.40–1.50)	sex

	Snuff				9	23	1.47 (0.80–2.80)

	ST				10	38	1.08 (0.68–1.70)h	none

Stockwell and Lyman 1986 [70]

- nasal cancer	ST	Ever	Any	M+F	11	1	2.93 (0.40–21.66)g	none

- larynx cancer	ST	Ever	Any	M+F	12	6	2.02 (0.84–4.86)g	none

Young et al. 1986 [71]

- larynx cancer	ST	Ever	Any	M	13	NA	no association	none

Lewin et al. 1998 [102]

- larynx cancer	Snuff	Current	Any	M	14	15	1.00 (0.50–1.90)	age, alc, res, smok

		Former			15	9	0.80 (0.40–1.70)

		Ever			16	24	0.90 (0.50–1.50)


GroupNo.	Description	Body site whereS. aureus detectedin Parsonnet 2005studya	Ab present inParsonnet 2005studyb	No. of subjectsenrolledc	No. of subjectscompleting allvisits

1	Carriers of SA TSST-1(+)	Vagina	Yes or No	14	11

2	Carriers of SA TSST-1(+)	Nose or anus	Yes	78	64

3	Carriers of SA TSST-1(-)	Any site	Yes	69	49

4	Non-carriers	None	Yes	75	58

5	Negative Ab control(Carriers or Non-carriers)	Any site	No	75	61

GroupNo.	Description	Body site whereS. aureus detectedin Parsonnet 2005studya	Ab present inParsonnet 2005studyb	No. of subjectsenrolledc	No. of subjectscompleting allvisits

4	Non-carriers	None	Yes	75	58

5	Negative Ab control(Carriers or Non-carriers)	Any site	No	75	61


Gay/Lesbian

 	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Outcome	OR*	(95% CI)	OR*	(95% CI)	 	Z Value	P-Value

Current Smoker	1.843	(1.17, 2.92)	1.812	(1.14, 2.88)	1.68	1.846	0.064

BMI (Overweight/Obese)	1.128	(0.78, 1.64)

Lifetime History of Drug Use (Excluding Marijuana)	1.786	(1.10, 2.91)	1.766	(1.09, 2.87)	1.12	1.4863	0.137

Lifetime History of Marijuana Use	1.753	(1.09, 2.82)	1.746	(1.09, 2.81)	0.40	1.50534	0.132

Risky Drinking (5 or more drinks) in Past 12 months	1.01	(0.61, 1.69)

Lifetime Period of Risky Drinking	1.271	(0.76, 2.12)

Bisexual

 	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Outcome	OR*	(95% CI)	OR*	(95% CI)	 	Z Value	P-Value

Current Smoker	2.124	(1.65, 2.73)	2.044	(1.59, 2.63)	3.77	3.04054	0.0023

BMI (Overweight/Obese)	0.897	(0.61, 1.31)	 	-	-	-	-

Lifetime History of Drug Use (Excluding Marijuana)	3.381	(2.24, 5.10)	3.301	(2.20, 4.96)	2.37	1.93298	0.0532

Lifetime History of Marijuana Use	2.928	(2.05, 4.19)	2.901	(2.02, 4.16)	0.92	3.44351	<0.001

Risky Drinking (5 or more drinks) in Past 12 months	1.499	(1.05, 2.15)	Cannot Estimate

Lifetime Period of Risky Drinking	2.901	(1.67, 5.04)	Cannot Estimate

Gay/Lesbian

	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Lifetime History of Marijuana Use	1.753	(1.09, 2.82)	1.746	(1.09, 2.81)	0.40	1.50534	0.132

Risky Drinking (5 or more drinks) in Past 12 months	1.01	(0.61, 1.69)

Lifetime Period of Risky Drinking	1.271	(0.76, 2.12)

Bisexual

	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Outcome	OR*	(95% CI)	OR*	(95% CI)		Z Value	P-Value

Current Smoker	2.124	(1.65, 2.73)	2.044	(1.59, 2.63)	3.77	3.04054	0.0023

BMI (Overweight/Obese)	0.897	(0.61, 1.31)		-	-	-	-

Lifetime History of Drug Use (Excluding Marijuana)	3.381	(2.24, 5.10)	3.301	(2.20, 4.96)	2.37	1.93298	0.0532

Lifetime History of Marijuana Use	2.928	(2.05, 4.19)	2.901	(2.02, 4.16)	0.92	3.44351	<0.001

Risky Drinking (5 or more drinks) in Past 12 months	1.499	(1.05, 2.15)	Cannot Estimate

Lifetime Period of Risky Drinking	2.901	(1.67, 5.04)	Cannot Estimate


Scenario	MP Windows (s)	PRN

1	8–16	27

	21–25	11, 22


AU	95%	z s	P value (Area=0.5)		Sensi	Specifici


Diagnostic Stage	Diagnostic Modality	Sensitivity (%)

Central	Peripheral

Initial Diagnosis	Sputum cytology	71	49

Bronchoscopy	88	78

 Washings	47	43

 Brushings	56	54

 Biopsy	74	57

Radiologically guided transthoracic biopsy	-	90

Radial probe EBUS	-	73

Electromagnetic navigation	-	68

Cryobiopsy	95	74

Linear EBUS TBNA	82	-

Mediastinal Staging	Bronchoscopic TBNA	78

Linear EBUS TBNA	89

EUS	89

EUS + EBUS	91

Video assisted surgical mediastinoscopy	89

Diagnostic Stage	Diagnostic Modality	Sensitivity (%)

Central	Peripheral

Initial Diagnosis	Linear EBUS TBNA	82	-

Mediastinal Staging	Bronchoscopic TBNA	78

Linear EBUS TBNA	89

EUS	89

EUS + EBUS	91

Video assisted surgical mediastinoscopy	89


MMP	ANOVA	Post Test Results

pMMP-9	p = 0.0817	No significant differences.

aMMP-9	p = 0.0944	No significant differences.

pMMP-2	p = 0.0010	pH 5.6 (24 h) < Positive Control (24 h) (p < 0.05)

		pH 9 (24 h) < Positive Control (24 h) (p < 0.01)

		Negative Control (72 h) < Positive Control (24 h) (p < 0.001)

		Positive Control (72 h) < Positive Control (24 h) (p < 0.05)

		pH 4 (72 h) < Positive Control (24 h) (p < 0.05)

		pH 5.6 (72 h) < Positive Control (24 h) (p < 0.05)

		Negative Control (72 h) < pH 4 (24 h) (p < 0.05)

aMMP-2	p = 0.0019	pH 9 (24 h) < Positive Control (24 h) (p < 0.01)

		pH 9 (24 h) < pH 4 (24 h) (p < 0.05)

		Negative Control (72 h) < Positive Control (24 h) (p < 0.01)

		Negative Control (72 h) < pH 4 (24 h) (p < 0.05)


	Health consumer

Health professional	Integration	Assimilation	Separation	Individualism (Marginalization)

Integration	Consensual	Problematic	Conflictual	Problematic

Assimilation	Problematic	Consensual	Conflictual	Problematic

Separation	Conflictual	Conflictual	Conflictual	Conflictual

Individualism	Conflictual	Conflictual	Conflictual	Conflictual


Immuno-staining	DLBCL component positive	LP cells positive	Reduced expression in DLBCL component	Enhanced expression in DLBCL component	Identical expression in DLBCL and NLPHL component	Identical expression in DLBCL and NLPHL in simultaneous cases

Bcl6	33/33 (100%)	33/33 (100%)	3%	0%	97%	96%

CD79a	33/33 (100%)	33/33 (100%)	0%	33%	67%	62%

CD19	32/33 (97%)	25/32 (78%)	3%	66%	31%	32%

CD75	31/33 (94%)	32/33 (97%)	12%	9%	79%	81%


Name	Position	Length	Orientation	Distance	Located on	Accession


Variable	Value

 Age (years)	63 (58–73)

 Sex ratio (male/female)	16/9

 Body mass index (kg/m2)	26 (22–27)

 Euroscore 2 (%)	5 (3–8)

 Left ventricular ejection fraction (%)	60 (60–66)

 Preoperative serum creatinine (μmol/l)	76 (59–90)

 Glomerular filtration rate (ml/min/1.73 m2)	82 (75–91)

Comorbidities (n, %)

 Hypertension	15 (60)

 Chronic obstructive pulmonary disease	2 (8)

 Dyslipidemia	11 (45)

 Smokers	6 (24)

Type of surgery (n, %)

 Coronary surgery	8 (32)

 Valve surgery	12 (48)

 Combined surgery	2 (8)

 Other cardiac surgery	3 (12)

 Thoracic surgery	4 (16)

Chronic medications (n, %)

 Beta blockers	10 (40)

 Renin angiotensin system inhibitors	12 (48)

 Statins	11 (44)

 Antiplatelet agents	9 (36)

 Calcium channel blockers	5 (20)

 Nitrates	2 (8)

Vasoactive support

 Norepinephrine at baseline (μg/kg/min)	0.03 ± 0.10

During POAF

 Kaliemia (mmol/l)	4.1 ± 0.4

 Hemoglobin (g/dl)	10.8 ± 1.6

 SpO2 (%)	96.0 ± 1.8

Variable	Value

Euroscore 2 (%)	5 (3–8)

Left ventricular ejection fraction (%)	60 (60–66)

Preoperative serum creatinine (μmol/l)	76 (59–90)

Glomerular filtration rate (ml/min/1.73 m2)	82 (75–91)

Comorbidities (n, %)

Hypertension	15 (60)

Chronic obstructive pulmonary disease	2 (8)

Dyslipidemia	11 (45)

Smokers	6 (24)

Type of surgery (n, %)

Coronary surgery	8 (32)

Valve surgery	12 (48)

Combined surgery	2 (8)

Other cardiac surgery	3 (12)

Thoracic surgery	4 (16)

Chronic medications (n, %)

Beta blockers	10 (40)

Renin angiotensin system inhibitors	12 (48)

Statins	11 (44)

Antiplatelet agents	9 (36)

Calcium channel blockers	5 (20)

Nitrates	2 (8)

Vasoactive support

Norepinephrine at baseline (μg/kg/min)	0.03 ± 0.10

During POAF

Kaliemia (mmol/l)	4.1 ± 0.4

Hemoglobin (g/dl)	10.8 ± 1.6

SpO2 (%)	96.0 ± 1.8


	Prevention protocol	Treatment protocol

	DIO	L. laricina	L. laricina	DIO	L. laricina	L. laricina

	125 mg/kg	250 mg/kg	125 mg/kg	250 mg/kg

Retroperitoneal fat pad (g)	1.34 ± 0.05	1.26 ± 0.04	1.14 ± 0.05*	1.51 ± 0.08	1.35 ± 0.24	1.44 ± 0.04


Substance name	Mechanism of action	Clinical trial, design and results	Reference

TAK-242 (Resatorvid)	Binds covalently to Cys747 of TLR4-TIR domain and blocks TLR4/TIRAP and TLR4/TRAM interactions	Randomized, double-blind, placebo-controlled phase 2 trial (274 patients). Failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure.	[124]

Eritoran (E5564)	Lipid A mimic, binds to MD-2	Phase 2, double-blind, placebo-controlled, ascending-dose study (152 patients). Eritoran was well tolerated but did not attenuated systemic inflammation significantly.	[127]

Randomized, double-blind, placebo-controlled, multinational phase 3 trial (1961 patient). Treatment did not improve 28-day survival.	[131]

Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial (293 patients). Eritoran was well tolerated but the mortality was not decreased significantly.	[132]

Substance name	Mechanism of action	Clinical trial, design and results

TAK-242 (Resatorvid)	Binds covalently to Cys747 of TLR4-TIR domain and blocks TLR4/TIRAP and TLR4/TRAM interactions	Randomized, double-blind, placebo-controlled phase 2 trial (274 patients). Failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure.

Eritoran (E5564)	Lipid A mimic, binds to MD-2	Phase 2, double-blind, placebo-controlled, ascending-dose study (152 patients). Eritoran was well tolerated but did not attenuated systemic inflammation significantly.

Randomized, double-blind, placebo-controlled, multinational phase 3 trial (1961 patient). Treatment did not improve 28-day survival.

Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial (293 patients). Eritoran was well tolerated but the mortality was not decreased significantly.


	All patients	Patients with OS >50 months	Patients with OS <50 months	Pvalue

ORR (%)*	44.9	82.6	17.9	<0.00001

CBR (%)*	63.3	100	35.7	<0.00001

TTF*	10	26	5	0

TTP*	18	34	5	0

OS*	38	68	17	<0.00001

OS from diagnosis of MBC	52	113	20	<0.00001

Number Of chemotherapy regimens*	1 (0-3)	1 (0-3)	1 (0-3)	0.66

Number of chemotherapy regimens for BC	3 (1-7)	4 (1-7)	4 (1-6)	0.36

Number of chemotherapy regimens for MBC	3 (1-7)	3 (1-7)	3 (1-5)	0.2

	All patients	Patients with OS >50 months	Patients with OS <50 months	Pvalue

OS*	38	68	17	<0.00001

OS from diagnosis of MBC	52	113	20	<0.00001

Number Of chemotherapy regimens*	1 (0-3)	1 (0-3)	1 (0-3)	0.66

Number of chemotherapy regimens for BC	3 (1-7)	4 (1-7)	4 (1-6)	0.36

Number of chemotherapy regimens for MBC	3 (1-7)	3 (1-7)	3 (1-5)	0.2


 	PD (n = 14)	CON (n = 17)	P value

 	Means ± SD	Means ± SD

Age (years)	62.79 ± 4.59	61.35 ± 4.27	0.376

Gender*	11 M/3 F	13 M/4 F	0.889

Disease duration (years) 	2.46 ± 1.43	—	—

UPDRS score

 Part I—mood/cognition 	2.93 ± 1.14	—	—

 Part II—activities of daily living 	9.93 ± 2.27	—	—

 Part III—motor examination 	21.79 ± 5.66	—	—

 Part IV—complications of therapy 	0	—	—

MMSE score	23.93 ± 2.13	—	—

VAS	4.77 ± 1.30	5.69 ± 1.25	0.064

WST	37.01 ± 1.44	35.74 ± 1.39	0.022

HPT	47.74 ± 2.09	45.33 ± 3.44	0.042


	SERPINB9	CD83	CD9

	Pool	Indiv	Pool	Indiv	Pool	Indiv

Control	1	1	1	1	1	1

MS	0.5	2.47	1.1	0.58	1.23	3.5


QoL Domains	Mesor	Amplitude	Circadian Quotient	Rhythm Quotient	24-hr Correlation	Night-day Sleep Balance

EORTC Symptom Items

Fatigue			-0.4	-0.41		-0.52

Pain				-0.39

Loss of Appetite						-0.47

EORTC Functional Domains

Social				.34

Role						0.56

Cognitive						0.45

EORTC Global Health item					0.53

Ferrans-Powers QLI Domains

Health/Function	0.44	0.51			0.45	0.39

Social/Economic		0.38	0.39			0.40

Psychological Spiritual		.45		0.4		0.45

Family		0.45

QoL Domains	Mesor	Amplitude	Circadian Quotient	Rhythm Quotient	24-hr Correlation	Night-day Sleep Balance

EORTC Symptom Items

Fatigue			-0.4	-0.41		-0.52

Pain				-0.39

Loss of Appetite						-0.47

EORTC Functional Domains

Socia				.

l				34

Role						0.56

Cognitive						0.45

EORTC Global Health item					0.53

Ferrans-Powers QLI Domains

Health/Function	0.44	0.51			0.45	0.39

Social/Economic		0.38	0.39			0.40

Psychological Spiritual		.45		0.4		0.45

Family		0.45


Case	Signs/symptoms	Treatment	R

1	Anorexia, weight loss, fasting hypoglycemia, and mental aberrations	IVH, Di	[12]

2	Weakness, anorexia, orthostatic dizziness, failure to lactate, and weight loss	BB, C	[13]

3	Myalgia, anorexia, nausea, vomiting, weight loss, and failure to lactate	IVH, C 	[14]

4	Lethargy, anorexia, vomiting, and weight loss	IVH, C, AT, RAI	[15]

5	Fatigue, weakness, nausea, vomiting, myalgia, arthralgia, and weight loss	C	[16]

6	Lethargy, myalgia, arthralgia, myopathy, nausea, vomiting, anorexia, weight loss, and failure to lactate	C, AT	[17]

7	Confusion, tachycardia, and dehydration	C, RAI	[17]

8	Disturbed mental state, severe nausea, vomiting, increased thirst, polyuria, and weight loss	AT, C, DDAVP	[4]

9	Anorexia, diarrhea, night sweats, myalgia, and weight loss	IVH, BP, AT, C	[18]

10	Headache, anorexia, weakness, fever, tachycardia, mental changes, and failure to lactate	C, IVH, KI, AT, BB 	[19]

11	Nausea, vomiting, fever, and lethargy	C	[7]

12	Anorexia, nausea, vomiting, and severe dehydration	C, IVH	[20]

13	Vomiting and diarrhea	IVH, BB, C	[21]

PC	Vomiting, nausea, constipation, and weight loss	IVH, C, Di, BP, AT, BB

Case	Signs/symptoms	Treatment	R

1	Anorexia, weight loss, fasting hypoglycemia, and mental aberrations	IVH, Di	[12]

2	Weakness, anorexia, orthostatic dizziness, failure to lactate, and weight loss	BB, C	[13]

3	Myalgia, anorexia, nausea, vomiting, weight loss, and failure to lactate	IVH, C	[14]

4	Lethargy, anorexia, vomiting, and weight loss	IVH, C, AT, RAI	[15]

5	Fatigue, weakness, nausea, vomiting, myalgia, arthralgia, and weight loss	C	[16]

6	Lethargy, myalgia, arthralgia, myopathy, nausea, vomiting, anorexia, weight loss, and failure to lactate	C, AT	[17]

7	C	C, RAI	[1

	onfusion, tachycardia, and dehydration		7]

8	Disturbed mental state, severe nausea, vomiting, increased thirst, polyuria, and weight loss	AT, C, DDAVP	[4]

9	Anorexia, diarrhea, night sweats, myalgia, and weight loss	IVH, BP, AT, C	[18]

10	Headache, anorexia, weakness, fever, tachycardia, mental changes, and failure to lactate	C, IVH, KI, AT, BB	[19]

11	Nausea, vomiting, fever, and lethargy	C	[7]

12	Anorexia, nausea, vomiting, and severe dehydration	C, IVH	[20]

13	Vomiting and diarrhea	IVH, BB, C	[21]

PC	Vomiting, nausea, constipation, and weight loss	IVH, C, Di, BP, AT, BB


	Community-based organization Naloxone distribution	Traditional prescription	Pharmacy-based Naloxone models

CPA	Standing medication order	Protocol order	Pharmacist prescribing

Who issues prescription?	Prescriber via standing order	Prescriber	Non-pharmacist prescriber	Non-pharmacist prescriber	Licensing board	Pharmacist

Medical professionals required	Varies by state: prescriber, state/local health department	Prescriber + pharmacist	Prescriber + pharmacist	Prescriber + pharmacist	Pharmacist	Pharmacist

Potential recipients	Individuals served by the community-based organization	Patients of the prescriber	Varies by state	Anyone meeting criteria specified by prescriber	Anyone meeting criteria specified by licensing board	Anyone for whom medication is indicated

Target overdose risk population served	People who use drugs (prescription opioids, heroin) who access the community-based organization*	People who use drugs who are in treatment/visit a prescriber*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*

Patients prescribed opioids who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*

Geographic reach	Limited to where community-based organizations are located and operate	Limited to where the prescriber practices	Any participating pharmacy within the state	Any participating pharmacy within the state	Any participating pharmacy within the state	Limited to where the pharmacist practices

	Community-based organization Naloxone distribution	Traditional prescription	Pharmacy-based Naloxone models

CPA	Standing medication order	Protocol order	Pharmacist prescribing

Medical professionals required	Varies by state: prescriber, state/local health department	Prescriber + pharmacist	Prescriber + pharmacist	Prescriber + pharmacist	Pharmacist	Pharmacist

Potential recipients	Individuals served by the community-based organization	Patients of the prescriber	Varies by state	Anyone meeting criteria specified by prescriber	Anyone meeting criteria specified by licensing board	Anyone for whom medication is indicated

Target overdose risk population served	People who use drugs (prescription opioids, heroin) who access the community-based organization*	People who use drugs who are in treatment/visit a prescriber*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*

Patients prescribed opioids who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*

Geographic reach	Limited to where community-based organizations are located and operate	Limited to where the prescriber practices	Any participating pharmacy within the state	Any participating pharmacy within the state	Any participating pharmacy within the state	Limited to where the pharmacist practices


Group (n)	M/F,n(missing data)	Age at death, yr (mean ± SD)	Sections available,n

Frontal	Temporal	Hippocampal

Controls (32)	14/18	72.0 ± 21.0	19	32	31

AD (46)	2	72.0 ± 	46		41


	Patientsn	Tested forvitamin Dlevels (%)	Deficientor severelydeficienta (%)	Minimum level ofvitamin D for bonehealthb (%)	Vitamin D at> 75 nmol/L

			6 (75	2 (	0 (

	Patientsn	Tested forvitamin Dlevels (%)	Deficientor severelydeficienta (%)	Minimum level ofvitamin D for bonehealthb (%)	Vitamin D at> 75 nmol/L

Male	14	8 (57)	)	25)	0)

Female	42	19 (45.2)	15 (79)	4 (21)	0 (0)

White	39	18 (46.1)	13 (72.2)	5 (27.8)	0 (0)

BME	17	9 (52.9)	9 (100)	0 (0)	0 (0)

Total	56	27 (48)	22 (81.5)	5 (18.5)	0 (0)


Term	Count	P-value	Genes

Regulation of transcription, DNA-dependent	105	4.82E–06	REST, RORA, ZNF254, HOXC6, TDGF3, GATA6, TDGF1, OLIG2, MLL3, PITX2, NODAL, EMX2, ZNF814, EOMES, SUZ12, HES5, SOX7, LIN28A, NR2C2, ARX, FOXH1, LHX9, DNMT3A, SALL4, FOXA2, NR6A1, PAX3, GLI2, POU5F1, HEY2, ZNF720, SOX10, NANOG, DMRT3, OTX2, RUNX1T1, SPEN, HAND1, ISL1, POU5F1B, ATRX, RBAK, THRAP3, PBX2

Embryonic morphogenesis	26	3.44E–04	RBP4, FOXA2, PAX3, GLI2, TDGF3, SPRY2, HAND1, PRKRA, TDGF1, CEP290, NODAL, EOMES, PCDH8, CFC1, DKK1, SALL4, GNAQ, HOXB6, LRP6, PTCH1, MAB21L2, PBX2

Lung development	11	0.004697	SPRY2, RBP4, FOXA2, PDGFA, GATA6, DHCR7, NODAL, VEGFA, GLI2, FOXP1, KDR

Regulation of neurogenesis	13	0.026608	PHOX2B, NBN, BMP2, FOXA2, REST, ISL1, GLI2, RUFY3, HES5, CCND2, NUMB, NEFM, ASPM

Forebrain development	16	7.60E–04	OTX2, EMX2, GLI2, ISL1, AHSG, ARX, SALL3, ATRX, FEZF2, DKK1, GNAQ, NUMB, PAFAH1B1, LRP8, RELN, ASPM

Neuron differentiation	32	8.12E–04	FGFR1, FOXA2, ONECUT2, GRIN3A, PAX3, RORA, GLI2, PTEN, CXCL12, KLHL1, ARX, KAL1, NUMB, CEP290, OLIG1, PAFAH1B1, OLIG2, RET, BHLHE22, OTX2, EMX2, LIFR, ISL1, CDKN1C, SALL3, FEZF2, EPHA4, ADM, GNAQ, HES5, VEGFA, RELN

Cerebral cortex development	6	0.008017	ARX, EMX2, LRP8, PAFAH1B1, RELN, AHSG

Telencephalon development	7	0.038287	ARX, SALL3, EMX2, LRP8, PAFAH1B1, RELN, AHSG

Term	Count	P-value	Genes

Lung development	11	0.004697	SPRY2, RBP4, FOXA2, PDGFA, GATA6, DHCR7, NODAL, VEGFA, GLI2, FOXP1, KDR

Regulation of neurogenesis	13	0.026608	PHOX2B, NBN, BMP2, FOXA2, REST, ISL1, GLI2, RUFY3, HES5, CCND2, NUMB, NEFM, ASPM

Forebrain development	16	7.60E–04	OTX2, EMX2, GLI2, ISL1, AHSG, ARX, SALL3, ATRX, FEZF2, DKK1, GNAQ, NUMB, PAFAH1B1, LRP8, RELN, ASPM

Neuron differentiation	32	8.12E–04	FGFR1, FOXA2, ONECUT2, GRIN3A, PAX3, RORA, GLI2, PTEN, CXCL12, KLHL1, ARX, KAL1, NUMB, CEP290, OLIG1, PAFAH1B1, OLIG2, RET, BHLHE22, OTX2, EMX2, LIFR, ISL1, CDKN1C, SALL3, FEZF2, EPHA4, ADM, GNAQ, HES5, VEGFA, RELN

Cerebral cortex development	6	0.008017	ARX, EMX2, LRP8, PAFAH1B1, RELN, AHSG

Telencephalon development	7	0.038287	ARX, SALL3, EMX2, LRP8, PAFAH1B1, RELN, AHSG


Type of complication 	Prevalence N (%)

Retinopathy	6 (0.9)

LVH	12 (2)

IHD	51 (8.3)

HF	75 (12.2)

CKD	20 (3.3)

Hypertensive urgency	39 (6.4)

Sexual dysfunction	4 (0.67)

Stroke	34 (5.5)

AF	6 (0.9)

Total TOD	247 (100.0)


Variable	Active group	Control group	df	x2/ T	P

	N = 80	N = 80

Foot care practice*	4.77 ± 0.77	4.45 ± 0.83	158	−2.54	0.01

(day/week)


Treatment	Conc. (μg/ml)	Mean absorbance ± SD	Percentage inhibition of haemolysis

Heated solution	Unheated solution

Control	-	0.67 ± 0.13	0.3 ± 0.01

Extract	100	0.25 ± 0.04**	0.4 ± 0.01	66.46 ± 2.89

200	0.28 ± 0.04**	0.08 ± 0.03	65.14 ± 4.58

Treatment	Conc. (μg/ml)	Mean absorbance ± SD	Percentage inhibition of haemolysis

Heated solution	Unheated solution

Extract	400	0.42 ± 0. 07**	0.12 ± 0.03	46.53 ± 2.52

600	0.42 ± 0.06**	0.25 ± 0.06	61.88 ± 4.51

	800	0.43 ± 0.09**	0.38 ± 0.08	86.67 ± 3.06

Indomethacin	200	0.05 ± 0.01***	0.02 ± 0.00	95.32 ± 3.51


Malalignment parameter	Difference compared to pre-opMedian (IQR)	Significancea

Cutting guide (n = 4)	Visualisation (n = 4)

Coronal shift in mm, ulnar (−), radial (+)	3.1 (1.9 to 10.0)	−2.6 (−3.0 to 3.5)	0.200

Sagittal shift in mm, volar (−), dorsal (+)	10.2 (−7.3 to 18.1)	−6.7 (−26.4 to −2.6)	0.200

Radial length in mm	2.2 (−2.0 to 15.7)	4.3 (0.3 to 5.4)	0.686

Palmar tilt in deg, dorsal (−), volar (−)	−6.8 (−24.5 to 4.4)	8.5 (5.2 to 14.9)	0.114

Radial inclination in deg, ulnar (−), radial (+)	−3.2 (−9.3 to 5.7)	0.3 (−11.4 to 5.3)	1.000

Axial rotation in deg, pronation (−), supination (+)	23.0 (11.5 to 30.6)	1.8 (−13.1 to 30.0)	0.343

Malalignment parameter	Difference compared to pre-opMedian (IQR)

Cutting guide (n = 4)

Coronal shift in mm, ulnar (−), radial (+)	3.1 (1.9 to 10.0)

Sagittal shift in mm, volar (−), dorsal (+)	10.2 (−7.3 to 18.1)

Radial length in mm	2.2 (−2.0 to 15.7)

Palmar tilt in deg, dorsal (−), volar (−)	−6.8 (−24.5 to 4.4)

Radial inclination in deg, ulnar (−), radial (+)	−3.2 (−9.3 to 5.7)

Axial rotation in deg, pronation (−), supination (+)	23.0 (11.5 to 30.6)


Analyte	Concn (ng/ml)

Low	High

Amodiaquine	4.0	4,192

Desethylamodiaquine	4.0	4,192

Lumefantrine	25	20,000

Chloroquine	4.0	4,192

Desethylchloroquine	4.0	4,192

Dihydroartemisinin	1.6	2,875

Piperaquine	1.2	575

Mefloquine	70	4,000

Carboxymefloquine	70	4,000

Primaquine	10	400

Carboxyprimaquine	50	4,000


	Panitumumab + mFOLFOX6 (n = 88)	Bevacizumab + mFOLFOX6 (n = 82)*

Median DoR, months (95% CI)	11.4 (10.0, 16.3)	9.0 (7.6, 9.5)

 HR† (95% CI)	0.59 (0.39, 0.88)

 p value‡	0.011

Median TTR, months (95% CI)	2.3 (1.9, 3.7)	3.8 (2.1, 5.7)

 HR† (95% CI)	1.19 (0.81, 1.74)

 p value‡	0.37

Median DpR, % (Q1, Q3)	65.0 (45.7, 89.5)	46.3 (29.5, 63.3)

 p value¶	0.0018

Any resection, n (%)	12 (14)	9 (11)

 Liver only§	9 (75)	6 (67)

Complete resection	9 (10)	7 (9)

 Liver only^	7 (78)	6 (86)

Time to resection, months – median (range)	5.1 (3–19)	4.4 (3–12)

Progression-free at 6 months, n (%)

 Patients with resection	8/12 (67)	4/9 (44)

 Patients without resection	45/76 (59)	48/73 (66)

Alive at 2 years, n (%)

 Patients with resection	8/12 (67)	8/9 (89)

 Patients without resection	18/76 (24)	12/73 (16)

	Panitumumab + mFOLFOX6 (n = 88)	Bevacizumab + mFOLFOX6 (n = 82)*

p value¶	0.0018

Any resection, n (%)	12 (14)	9 (11)

Liver only§	9 (75)	6 (67)

Complete resection	9 (10)	7 (9)

Liver only^	7 (78)	6 (86)

Time to resection, months – median (range)	5.1 (3–19)	4.4 (3–12)

Progression-free at 6 months, n (%)

Patients with resection	8/12 (67)	4/9 (44)

Patients without resection	45/76 (59)	48/73 (66)

Alive at 2 years, n (%)

Patients with resection	8/12 (67)	8/9 (89)

Patients without resection	18/76 (24)	12/73 (16)


		High-risk subject	Low-risk subject

		N	Meana	CI	N	Meana	CI	P


Gene	Encoded protein	Fold change	Cell cycle

AURKA	Aurora kinase A	−2.712	STOP

AURKB	Aurora kinase B	−4.146	STOP

CCNA2	Cyclin A2	−4.652	STOP

CCNB1	Cyclin B1	−5.752 −5.820 −5.857	STOP

CCNB2	Cyclin B2	−3.392	STOP

CCND1	Cyclin D1	−2.476	STOP

CCND3	Cyclin D3	−1.539	STOP

CCNE1	Cyclin E1	−1.777	STOP

CCNE2	Cyclin E2	−2.847	STOP

CCNF	Cyclin F	−3.211	STOP

CDC6	Cell division cycle 6	−1.936	STOP

CDC20	Cell division cycle 20	−3.113	STOP

CDC25B	Cell division cycle 25B	−1.636	STOP

CDC25C	Cell division cycle 25C	−2.414	STOP

CDC45	Cell division cycle 45	−1.769	STOP

CDCA2	Cell division cycle associated 2	−3.461	STOP

CDCA3	Cell division cycle associated 3	−3.003	STOP

CDCA5	Cell division cycle associated 5	−3.053	STOP

CDCA7L	Cell division cycle associated 7-like	−4.123	STOP

CDCA8	Cell division cycle associated 8	−3.467	STOP

CDK1	Cyclin-dependent kinase 1	−3.227	STOP

CDK15	Cyclin-dependent kinase 15	1.618	GO

CDK19	Cyclin-dependent kinase 19	1.619	GO

CDK5R1	Cyclin-dependent kinase 5, regulatory subunit 1 (p35)	1.597	—

CENPA	Centromere protein A	−1.895	STOP

CENPE	Centromere protein E, 312 kDa	−4.140	STOP

CENPF	Centromere protein F, 350/400 kDa	−3.927	STOP

CENPI	Centromere protein I	−2.899	STOP

CENPK	Centromere protein K	−2.813	STOP

CENPL	Centromere protein L	−1.864	STOP

CENPM	Centromere protein M	−3.407	STOP

CENPN	Centromere protein N	−2.465	STOP

CENPU	Centromere protein U	−1.624	STOP

SKA1	Spindle and kinetochore associated complex subunit 1	−1.532	STOP

SKA2	Spindle and kinetochore associated complex subunit 2	−1.582	STOP

SKA3	Spindle and kinetochore associated complex subunit 3	−3.490	STOP

SKP2	S-phase kinase-associated protein 2, E3 ubiquitin protein ligase	−1.845	STOP

SPC25	SPC25, NDC80 kinetochore complex component	−4.148	STOP


	Criteria	Assessment

1	A diagnosis of PD	Queen's Square Brain Bank Criteria

2	PD developed prior to the onset of dementia	Patient/caregiver history or ancillary records

3	PD associated with a decreased global cognitive efficiency	MMSE < 26

4	Cognitive deficiency severe enough to impair daily life	Caregiver interview or pill questionnaire

5	Impairment of more than one cognitive domain	Impairment of at least two of the following domains

		Attention

		Executive function

		Visuo-constructive ability

		Memory

	Criteria	Assessment

1	A diagnosis of PD	Queen's Square Brain Bank Criteria

2	PD developed prior to the onset of dementia	Patient/caregiver history or ancillary records

3	PD associated with a decreased global cognitive efficiency	MMSE < 26

	Cognitive 	Caregiver intervi

	Criteria	Assessment

4	deficiency severe enough to impair daily life	ew or pill questionnaire

5	Impairment of more than one cognitive domain	Impairment of at least two of the following domains

		Attention

		Executive function

		Visuo-constructive ability

		Memory


Case/sex/age (years)	Initial treatment	Associated pseudocyst	Rebleeding	Secondary treatment	Length of follow-up (months)	Outcome

1/M/59	A	No	No	No	57	S

2/M/33	TG, L	No	No	No	38	S

3/M/46	E	Yes*	Yes	E‡, L, ED	4	D

4/F/71	E	No	Yes	E	18	S

5/M/36	Nearly TP, Sp	No	No	No	50	S

6/M/33	DP+	Yes*	Yes	E‡, L, ED	87	S

7/M/28	DP, Sp	Yes+	No	GC+	15	S

8/M/38	A, ED	Yes+	No	RD	51	S

9/M/35	DP, Sp	Yes	No	No	10	S

Case/sex/age (years)	Initial treatment	Associated pseudocyst	Rebleeding

1/M/59	A	No	No

2/M/33	TG, L	No	No

3/M/46	E	Yes*	Yes

4/F/71	E	No	Yes

5/M/36	Nearly TP, Sp	No	No

6/M/33	DP+	Yes*	Yes

7/M/28	DP, Sp	Yes+	No

8/M/38	A, ED	Yes+	No

9/M/35	DP, Sp	Yes	No

Secondary treatment	Length of follow-up (months)	Outcome

No	57	S

No	38	S

E‡, L, ED	4	D

E	18	S

No	50	S

E‡, L, ED	87	S

GC+	15	S

RD	51	S

No	10	S


Materials	Size (L = Length; W = Width; H = Height)

Grinding media	Steel ball (∅15 mm)	Square (L: 12 × W: 12 × H: 12 mm)	Cylinder (∅12 × H: 16 mm)

Iron ore particle	2–2.8 mm

Lifter	L: 40 × W: 20 × H: 10 mm	L: 40 × W: 20 × H: 15 mm	L: 40 × W: 20 × H: 20 mm

Materials

Grinding media

Iron ore particle

Lifter

Size (L = Length; W = Width; H = Height)

Steel ball (∅15 mm)	Square (L: 12 × W: 12 × H: 12 mm)	Cylinder (∅12 × H: 16 mm)

2–2.8 mm

L: 40 × W: 20 × H: 10 mm	L: 40 × W: 20 × H: 15 mm	L: 40 × W: 20 × H: 20 mm


Number of examined samples	n (%)

Pure buffalo samples	Adulterated samples

50	5 (10)	45 (90)

Number of examined samples

50	5 (10)	45 (90)


Menopausal symptoms	Number (%)	Severe	Very severe

Somatic

Sleeping problems	574 (78.7)	93	1

Hot flushes, sweating	508 (69.7)	157	75

Joint and muscular discomfort	500 (68.6)	86	0

Heart discomfort	360 (49.4)	0	0

Psychological

Physical and mental exhaustion	536 (73.5)	68	4

Depressive mood	402 (55.2)	109	12

Irritability	339 (46.5)	105	10

Anxiety	334 (45.8)	114	7

Urogenital

Dryness of vagina	449 (61.6)	102	4

Bladder problems	385 (52.8)	38	2

Sexual problems	343 (47.1)	56	6


Variable	No post-pyloric tubeMedian (IQR)	Post-pyloric tubeMedian (IQR)


Reading Task	Times New Roman	EasyReadingTM

Excerpt (t(531) = −32.12, p < 0.001)	3.50 ± 0.94	4.16 ± 1.09


Mechanism	Source	Description

Soluble CD25	RS cells	Prevent interaction of IL-2 with IL-2Rs

IL-10	RS cells, Tregs, cells of TME	Repress IL-2 and IFN-γ production

TGF-β	RS cells, Tregs, cells of TME	Repress IL-2 and IFN-γ productionDownregulate activating receptors (NKG2D, NKp30) and corresponding ligands (MICA, ULBP2, ULBP4)

IL-15	RS cells	Competition of RS cells and NK cells

CXCL9, CXCL10	RS cells (mainly EBV+)	Attract CD56bright–CD16dim NK cells

HLA-G and HLA-E	RS cells	Bind to inhibitory receptors on NK cells

Soluble MICA	RS cells	Endocytosis and degradation of NKG2D

BAG6/BAT3	RS cells	Endocytosis and degradation of NKp30

Rosetting	Macrophages, Tregs, Th2 T-helper cells	Physical shield of HRS cells from NK cells

c-FLIP	Overexpressed by RS cells	NK FasL-mediated apoptosis resistance

FasL	RS cells	Apoptosis of Fas-expressing NK cells

PD-L1	RS cells	Suppression of NK cell activation

MHC-I	RS cells (EBV+)	Bind to KIRs, inhibit NK cell activation


	PTSD Prevalence

PTSD Prevalence	-

War victims

Crime victims

Natural disaster

Road fatalities

Individual values

Security	0.35

Conformity	-0.32

Tradition	-0.09

Benevolence	0.002

Universalism	-0.36

Self-direction	-0.14

Stimulation	0.44

Hedonism	-0.04

Achievement	-0.31

Power	-0.25

Aggregated values

Traditional	0.13

Modern	0.28


Range of ages (months)	Average age (SD)	Rang of intelligibility	Average intelligibility scores (SD)


Variables	Lower-Grade Glioma	Glioblastoma

Numbers	170	133

Median age (range)	39 (10–75)	49 (8–81)

Sex (male)	103	86

Pathology (Astrocytic)	69	-

IDH1 mutational status	-	-

IDH1 mutation	100	18

IDH1 wild-type	34	78

1p/19q status	-	-

1p/19q co-deletion	34	2

No 1p/19q co-deletion	108	106

Variables

Numbers

Median age (range)

Sex (male)

Pathology (Astrocytic)

IDH1 mutational status

IDH1 mutation

IDH1 wild-type

1p/19q status

1p/19q co-deletion

No 1p/19q co-deletion


Characteristic	N (%) or Mean ± SD

Sex

 Female	183 (70.4 %)

 Male	77 (29.6 %)

Age (years)	38.8 (13.7)

Referral source

 Primary Care	231 (88.8 %)

 Respirologist	7 (2.7 %)

 Allergist	2 (0.8 %)

 Other	10 (3.8 %)

 Unknown	10 (3.8 %)

Diagnosis of atopy

 Allergic rhinitis	120 (46.2 %)

 Asthma	90 (34.6 %)

 Atopic dermatitis	61 (23.5 %)

 Venom allergy	5 (1.9 %)

 Drug allergy	42 (16.2 %)

 Urticaria	60 (23.1 %)

 Eczema	61 (23.5 %)

 Pollen food syndrome	35 (13.5 %)

Characteristic	N (%) or Mean ± SD

source

Primary Care	231 (88.8 %)

Respirologist	7 (2.7 %)

Allergist	2 (0.8 %)

Other	10 (3.8 %)

Unknown	10 (3.8 %)

Diagnosis of atopy

Allergic rhinitis	120 (46.2 %)

Asthma	90 (34.6 %)

Atopic dermatitis	61 (23.5 %)

Venom allergy	5 (1.9 %)

Drug allergy	42 (16.2 %)

Urticaria	60 (23.1 %)

Eczema	61 (23.5 %)

Pollen food syndrome	35 (13.5 %)


Absorbed dose to the thyroid (Gy)	Number of differentially expressed transcripts	Number of up- and down-regulated transcripts

0.05	1,225	↑ 338

 	 	↓ 887

0.5	1,636	↑ 480

 	 	↓ 1,156

1.4	544	↑ 284

 	 	↓ 260

11	575	↑ 412

 	 	↓ 163

32	425	↑ 293

 	 	↓ 132


	N (%)

Lesion location

Right upper lobe	40/68 (58.8)

Right middle lobe	21/68 (30.9)

Right lower lobe	22/68 (32.4)

Left upper lobe	33/68 (48.5)

Left lower lobe	21/68 (30.9)

Lesion distribution

Bilateral	30/68 (44.1)

Multilobar (≥3 lobes with abnormalities)	21/68 (30.9)

Lesion characteristics

Multiple nodules	42/68 (61.8)

Bronchiectasis	24/68 (35.3)

Cavity	13/68 (19.1)

Unilateral	9/68 (13.2)

Bilateral	4/68 (5.9)

Radiographic classification

Upper lobe cavitary pattern	12/68 (17.6)

Nodular bronchiectatic pattern	17/68 (25.0)

Unclassifiable	39/68 (57.4)

	N (%)

Right upper lobe	40/68 (58.8)

Right middle lobe	21/68 (30.9)

Right lower lobe	22/68 (32.4)

Left upper lobe	33/68 (48.5)

Left lower lobe	21/68 (30.9)

Lesion distribution

Bilateral	30/68 (44.1)

Multilobar (≥3 lobes with abnormalities)	21/68 (30.9)

Lesion characteristics

Multiple nodules	42/68 (61.8)

Bronchiectasis	24/68 (35.3)

Cavity	13/68 (19.1)

Unilateral	9/68 (13.2)

Bilateral	4/68 (5.9)

Radiographic classification

Upper lobe cavitary pattern	12/68 (17.6)

Nodular bronchiectatic pattern	17/68 (25.0)

Unclassifiable	39/68 (57.4)


Frequency	Sensitivity	Specificity

>0.20	99.70% (SNV 99.80%; indel 96.40%)	>99.5%


 	Normal	Borderline	Case

Anxiety

Baseline (n=37)	28	6	3

3 months (n=37)	30	5	2

6 months (n=28)	20	6	1

Depression

Baseline (n=37)	31	4	2

3 months (n=37)	31	4	2

6 months (n=28)	23	4	1

	Normal	Borderline	Case

3 months (n=37)	30	5	2

6 months (n=28)	20	6	1

Depression

Baseline (n=37)	31	4	2

3 months (n=37)	31	4	2

6 months (n=28)	23	4	1


Variants	P-value

Age at diagnosis	0.249

Gender	0.543

WBC at diagnosis	0.533

Bone marrow blasts	0.733

Peripheral blasts	0.406

FLT3-ITD positive	0.153

NPM1 mutation	0.031

CEBPA mutation	0.050


Coefficients	Estimate	Std. Error	t Value

(Intercept)	−1.222e + 02	1.251e + 02	−0.977

SWB	−4.421e − 03	4.916e − 02	−0.090

SDI	9.152e − 02	5.400e − 02	1.695

Dallas Theological Seminary	−5.706e − 01	1.473e + 00	−0.387

Denver Seminary	1.066e − 00	1.629e + 00	0.655

Gordon-Conwell Seminary	2.005e − 01	1.541e + 00	0.130

Oral Roberts University	2.190e − 02	2.209e + 00	0.010

Male	−3.381e + 00	1.364e + 00	−2.478

Birth Year	7.702e − 02	6.276e − 02	1.227

Non-Hispanic White or Euro-American	2.627e + 00	1.295e + 00	2.028

Latino or Hispanic American	8.577e + 00	2.872e + 00	2.987

Other/Multi-Racial	−5.138e + 00	3.248e + 00	−1.582


Organism	HIV seropositive cases(n = 144)	HIV seronegative subjects(n = 50)	P value (chi-square test)

C. parvum	87 (60.42%)	1 (2.00%)	0.0001

I. belli	13 (9.03%)	1 (2.00%)	0.082

Cyclospora spp.	2 (1.39%)	0	—


		Patient A

Parameters obtained from data	Hb (g dl−1)	10.5

CO (l min−1)	11.1

FIO2	0.8

Parameters obtained through optimization	VR (b min−1)	12.25

IE	0.28

RQ	0.6

VO2 (ml min−1)	294.3

	% of compartments collapsed	26

Parameters fixed for RM trials	Pv (cm H2O)	15

PEEP (cm H2O)	5

		Data	Model

Results of fitting the model to the data	PvO2 (mmHg)	47.3	49.5

PvCO2 (mmHg)	44.4	46.2

Qs/Qt (%)	28.6	31.8

PaO2 (mmHg)	153.7	149.9


	Recall	Precision	F-score

Any	79.46	78.45	78.95

Unrelated	60.26	70.59	65.02

Altered expression	77.96	79.90	78.91

Genetic variation	77.76	82.45	80.04

Regulatory modification	69.17	73.28	71.16

Overall	76.61	79.46	78.00


	All patients	PiCCO	PAC	p value

ICU mortality	34.7%	38.5%	30.0%	0.11

Hospital mortality	42.0%	45.8%	36.9%	0.12


Depressed	0 (0.0%)	2 (0.6%)	0.68

Residual/local recurrence	2 (1.2%)	6 (1.8%)

Histological classification (n)

Adenoma	52 (31.7%)	131 (38.9%)	0.47

Intramucosal cancer	89 (54.3%)	164 (48.7%)

SM superficial cancer	11 (6.7%)	20 (5.9%)

SM deep cancer	11 (6.7%)	19 (5.6%)

Others	0 (0.0%)	2 (0.6%)

Failure of retrieval	1 (0.6%)	1 (0.3%)


Key words	Other variations of key words

NCDs metabolic risk factors plus proximal determinants plus distal determinants plus geographic location	NCDs metabolic risk factors	High blood pressure, hypertension, high blood glucose, hyperglycemia, diabetes, high BMI, obesity, overweight, waist circumference, waist-hip ratio

Proximal determinants	Determinants, risk, diet, salt intake, tobacco, smoking, alcohol, physical inactivity, lifestyle

Distal determinants	Social determinants, education, income, gender, race, caste, ethnicity, socio-economic status, wealth index, income

South Asia	Nepal, India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Maldives, Afghanistan

Key words	Other variations of key words

NCDs metabolic	NCDs metabolic risk factors	High blood pressure, hypertension, high blood glucose, hyperglycemia, diabetes, high BMI, obesity, overweight, waist circumference, waist-hip ratio

Proximal determinants	Determinants, risk, diet, salt intake, tobacco, smoking, alcohol, physical inactivity, lifestyle

Distal determinants	Social determinants, education, income, gender, race, caste, ethnicity, socio-economic status, wealth index, income

South As	Nepal, India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Mal

Key words	Other variations of key words

 risk factors plus proximal determinants plus distal determinants plus geographic location	ia	dives, Afghanistan


	Prevalence (%) of PN (n = 300)	Univariate models

Odds ratio (OR) (95% CI)	p-value

D4T containing	196 (57)	0.8 (0.6, 1.2)	0.27


	Training set

Abstracts	3,500

Nr. characters	4,883,753

Nr. tokens	770,855

Abstracts with SACEM	2,916

Nr. mentions	29,478

Nr. chemicals	8,520

Nr. journals	193

TRIVIAL	8,832

SYSTEMATIC	6,656

ABBREVIATION	4,538

FORMULA	4,448

FAMILY	4,090

IDENTIFIER	672

MULTIPLE	202

NO CLASS	40


	FeNO	CalvNO	nNO

Asthma	Normal/increased	Normal/increased	Normal/increased

COPD	Normal/increased	Increased	NS

CF	Normal/decreased	Contradictory results	Decreased

PCD	Normal/decreased	Contradictory results	Decreased

Allergic rhinitis	Normal/increased	Normal	NS

BPD	Normal/decreased	Decreased	NS

HPS	Decreased	Increased	NS

PAH	Decreased	Increased	NS

SSc	Normal/decreased	Increased	NS

Rhinovirus infection	Increased	NS	NS

Allograft rejection	Increased	NS	NS

	FeNO	CalvNO

Asthma	Normal/increased	Normal/increased

COPD	Normal/increased	Increased

CF	Normal/decreased	Contradictory results

PCD	Normal/decreased	Contradictory results

Allergic rhinitis	Normal/increased	Normal

BPD	Normal/decreased	Decreased

HPS	Decreased	Increased

PAH	Decreased	Increased

SSc	Normal/decreased	Increased

Rhinovirus infection	Increased	NS

Allograft rejection	Increased	NS

nNO

Normal/increased

NS

Decreased

Decreased

NS

NS

NS

NS

NS

NS

NS


KEGGID	Pvalue	Count	Size	Term

4530	0.011	3	11	Tight junction

533	0.046	1	1	Keratan sulfate biosynthesis

604	0.046	1	1	Glycosphingolipid biosynthesis - ganglio series

1031	0.047	2	8	Glycan structures - biosynthesis 2

4620	0.047	2	8	Toll-like receptor signaling pathway

51	0.059	2	9	Fructose and mannose metabolism

4210	0.059	2	9	Apoptosis

3010	0.064	3	21	Ribosome

52	0.089	1	2	Galactose metabolism

512	0.089	1	2	O-Glycan biosynthesis

720	0.089	1	2	Reductive carboxylate cycle (CO2 fixation)

5213	0.089	1	2	Endometrial cancer

5218	0.089	1	2	Melanoma

5223	0.089	1	2	Non-small cell lung cancer

KEGGID	Pvalue	Count	Size	Term

51	0.059	2	9	Fructose and mannose metabolism

4210	0.059	2	9	Apoptosis

3010	0.064	3	21	Ribosome

52	0.089	1	2	Galactose metabolism

512	0.089	1	2	O-Glycan biosynthesis

720	0.089	1	2	Reductive carboxylate cycle (CO2 fixation)

5213	0.089	1	2	Endometrial cancer

5218	0.089	1	2	Melanoma

5223	0.089	1	2	Non-small cell lung cancer


Gene	Abbreviation	Teleost accession number	Transcript in the greater amberjack	In silico group	DE* male vs female gonads	Sex determining in

DM domain gene on the Y chromosome/ doublesex and mab-3-related transcription factor 1a	dmY/dmrt1a	Oryzias latipes NM_0 011 04680/ XM_004086451 unplaced scaffold	maker-jcf7180000931253-snap-gene-0.40-mRNA-1	SD7	Up in male gonads	Oryzias latipes [23, 65]

Gonadal soma-derived factor	gsdf	Oryzias latipes NM_0 011 77742 chr.12	Augustus-masked-jcf7180000916295-processed-gene-0.7-mRNA-1	SD17	Up in male gonads	Oryzias luzonensis [66]

Y chromosome–specific antimuellerian hormone	amhY	Oryzias latipes NM_0 011 04728 chr. 4	maker-jcf7180000931145-snap-gene-0.73-mRNA-2	SD4	Up in male gonads	Odontesthes hatcheri [67] HM153803.1

Antimuellerian hormone receptor 2	amhr2	Lates calcarifer KR492510 Oryzias latipes DQ499644.1 chr. 5 or 7	maker-jcf7180000889430-snap-gene-0.77-mRNA-5	SD1	No expression	Takifugu genus [68]

Sexually dimorphic o the Y chromosome	sdY	Salmonidae family	n/a	n/a	n/a	Salmonidae family [69]

SRY-box containing protein 3Y	sox3Y	Oryzias latipes AJ245396 chr.10	augustus-masked-jcf7180000920392-processed-gene-0.31-mRNA-1	SD18	Up in female gonads	Oryzias dancena [65]

Gene	Abbreviation	Teleost accession number	Transcript in the greater amberjack	In silico group	DE* male vs female gonads	Sex determining in

Gonadal soma-derived factor	gsdf	Oryzias latipes NM_0 011 77742 chr.12	Augustus-masked-jcf7180000916295-processed-gene-0.7-mRNA-1	SD17	Up in male gonads	Oryzias luzonensis [66]

Y chromosome–specific antimuellerian hormone	amhY	Oryzias latipes NM_0 011 04728 chr. 4	maker-jcf7180000931145-snap-gene-0.73-mRNA-2	SD4	Up in male gonads	Odontesthes hatcheri [67] HM153803.1

Antimuellerian hormone receptor 2	amhr2	Lates calcarifer KR492510 Oryzias latipes DQ499644.1 chr. 5 or 7	maker-jcf7180000889430-snap-gene-0.77-mRNA-5	SD1	No expression	Takifugu genus [68]

Sexually dimorphic o the Y chromosome	sdY	Salmonidae family	n/a	n/a	n/a	Salmonidae family [69]

SRY-box containing protein 3Y	sox3Y	Oryzias latipes AJ245396 chr.10	augustus-masked-jcf7180000920392-processed-gene-0.31-mRNA-1	SD18	Up in female gonads	Oryzias dancena [65]


Number of women (percentage)	357	(92%)

Median years of age (IQR)	52	(8)

Median years of age diagnosed with a pain disorder (IQR)a	30	(18)

Median PPI (IQR)	4	(3)

Median number of comorbid pain conditions (IQR)	3	(2)

Median number of current pain medications (IQR)	3	(3)

Median number of past pain medications (IQR)	6	(7)


	Nurses	Controls

N	32	30

Age (in years)	40.3 (11.3)	40.0 (12.3)

Sex (male/female)	7/25	3/27

Education	lower secondary school (Hauptschule)	7	4

Intermediate secondary school (Realschule)	18	22

Higher education entrance qualification (Abitur) (finished or enrolled)	5	4

University degree	2	0

Education	Intermediate secondary school (Realschule)	18	22

Higher education entrance qualification (Abitur) (finished or enrolled)	5	4

University degree	2	0


Dependent variable	Fivefolded cross-validated R2 (%)	Effect size, f2

MUSICIANS ONLY

Judgment line orientation	15	0.18

Letter-number sequencing	14	0.16

Tower rule violations	0	0.00

Letter fluency	0	0.00

CVLT-II SDFR	0	0.00

Grooved pegboard – dominant hand	29	0.21

Grooved pegboard – non-dominant hand	28	0.20

Dependent variable	Fivefolded cross-validated R2 (%)

MUSICIANS ONLY

Judgment line orientation	15

Letter-number sequencing	14

Tower rule violations	0

Letter fluency	0

CVLT-II SDFR	0

Grooved pegboard – dominant hand	29

Grooved pegboard – non-dominant hand	28


Welding Positions	No. of Butt Welds	Laser Beam Power, W	Traveling Speed, m/min	Heat Input, kJ/m

Vertical up	U01	2200	0.5	275

U02	2500	1.2	125

Vertical down	D01	2200	0.5	275

D02	2500	1.2	125

ns	 of Butt Welds	Laser Beam Power, W	peed, m/min	 Input, kJ/m

Vertical up	U01	2200	0.5	275

U02	2500	1.2	125

Vertical down	D01	2200	0.5	275

D02	2500	1.2	125


	Organs	n	Elks up to 2 years	n	Elks older than 3 years

Mean ± SD	Median	Mean ± SD	Median

Cu	Liver	8	18.61 ± 18.63	7.02	27	24.45 ± 30.03	10.77

Kidney	8	4.51 ± 2.43	3.72	27	5.13 ± 5.73	4.01


	Voyage

	1	2	3

Measure	Mean	SD	Mean	SD	Mean	SD

Wind chill (°C)	1.92	5.55	3.50	3.08	2.63	0.94


Category	Term	Count	P-value	Benjamini

KEGG_PATHWAY	Cytokine-cytokine receptor interaction	24	9.00E-07	1.30E-04

GOTERM_BP_FAT	Immune response	18	1.90E-03	2.50E-01

GOTERM_CC_FAT	Extracellular region part	15	1.60E-02	6.30E-01

GOTERM_MF_FAT	Cytokine activity	14	1.80E-03	1.90E-01

GOTERM_CC_FAT	Extracellular space	14	2.10E-02	4.90E-01

KEGG_PATHWAY	Natural killer cell mediated cytotoxicity	13	8.10E-04	5.50E-02

KEGG_PATHWAY	Chemokine signaling pathway	13	3.20E-02	2.90E-01

GOTERM_BP_FAT	Defense response	12	1.40E-02	4.60E-01

KEGG_PATHWAY	Jak-STAT signaling pathway	12	1.80E-02	2.00E-01

KEGG_PATHWAY	T cell receptor signaling pathway	10	1.50E-02	2.10E-01

KEGG_PATHWAY	Hematopoietic cell lineage	9	1.10E-02	1.80E-01

KEGG_PATHWAY	Toll-like receptor signaling pathway	9	2.30E-02	2.40E-01

KEGG_PATHWAY	NOD-like receptor signaling pathway	8	5.50E-03	1.40E-01

KEGG_PATHWAY	Allograft rejection	8	7.40E-03	1.60E-01

GOTERM_BP_FAT	Response to wounding	8	1.30E-02	5.10E-01

KEGG_PATHWAY	Fc epsilon RI signaling pathway	8	1.70E-02	2.10E-01

KEGG_PATHWAY	Asthma	7	2.00E-03	6.80E-02

GOTERM_BP_FAT	Inflammatory response	7	7.90E-03	3.90E-01

KEGG_PATHWAY	Cytosolic DNA-sensing pathway	7	8.20E-03	1.50E-01

KEGG_PATHWAY	Autoimmune thyroid disease	7	5.70E-02	4.20E-01

GOTERM_BP_FAT	Chemotaxis	6	1.40E-02	4.20E-01

GOTERM_MF_FAT	Cytokine binding	6	3.40E-02	8.60E-01

GOTERM_BP_FAT	Locomotors behavior	6	3.40E-02	7.10E-01

KEGG_PATHWAY	Graft-versus-host disease	6	4.30E-02	3.60E-01

INTERPRO	Immunoglobulin	6	4.50E-02	9.00E-01

KEGG_PATHWAY	Type I diabetes mellitus	6	6.90E-02	4.70E-01

GOTERM_BP_FAT	Behavior	6	7.90E-02	9.20E-01

GOTERM_BP_FAT	Cell migration	5	1.80E-03	4.30E-01

GOTERM_BP_FAT	Cell motility	5	3.30E-03	2.90E-01

INTERPRO	Small chemokine, C-C group, conserved site	5	5.50E-02	8.80E-01

GOTERM_BP_FAT	Leukocyte migration	4	6.40E-03	4.00E-01

INTERPRO	Chemokine receptor	4	6.40E-02	8.70E-01

GOTERM_MF_FAT	C-C chemokine receptor activity	4	7.20E-02	9.40E-01

GOTERM_MF_FAT	C-C chemokine binding	4	7.20E-02	9.40E-01

GOTERM_MF_FAT	Chemokine receptor activity	4	9.50E-02	9.40E-01


Time (min)	% Eluent A (0.1% TFA in dH2O)	% Eluent B (MeOH)	Flow Rate (mL/min)

0	15	85	1.5

6	0	10	1.5

Time (min)	% Eluent A (0.1% TFA in dH2O)	% Eluent B (MeOH)	Flow Rate (mL/min)

		0

25	0	100	1.5

26	15	85	1.5

35	15	85	1.5


Characteristics	OCP-patch (N = 30)	LTS-2 patch (N = 30)

Definition of reaction	At 24 h	At 30 h	At 24 h	At 30 h

 None	3 (10.0)	2 (6.7)	5 (16.7)	0

Oedema under the patch (any score)	NA	NA	25 (83.3)	30 (100)

 100 % of area oedematous (score 3)	NA	NA	17 (56.7)	27 (90.0)

> 50 % of area oedematous (score 2)	NA	NA	4 (13.3)	3 (10.0)

< 50 % of area oedematous (score 1)	NA	NA	4 (13.3)	0

 0 % of area oedematous (score 0)	NA	NA	5 (15.7)	0

 All reactions	27 (90.0)	28 (93.3)	25 (83.3)	30 (100)

Very easily visible reaction	18 (60.0)	24 (80.0)	22 (73.	19 (63.3)

Easily visible reaction	2 (6.7)	3 (10.0)	0	1 (3.3)

Attentive visual inspection required	7 (23.3)	1 (3.3)	3 (10.0)	10 (33.3)

Character of papules

 None	3 (10.0)	2 (6.7)	5 (16.7)	0

 Vague	4 (13.3)	1 (3.3)	3 (10.0)	0

 Pinheads	16 (53.3)	16 (53.3)	0	0

 Pinpoints	7 (23.3)	11 (36.7)	19 (63.3)	29 (96.7)

 Urticariform	0	0	3 (10.0)	1 (3.3)

Extension beyond patch area	2 (6.7)	8 (26.7)	0	0


Studies	Reported outcomes	Follow up period	Bias grade

Brar2008	Death, MI	9.7 months	-

I-LOVE IT 2	NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding	12 and 18 months	B

ISAR-SAFE	Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding	9 months	B

Tarantini2016	Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization	1 year	-

ARCTIC	Primary endpoints, Death, MI, ST, stroke, revascularization	17 months	B

OPTIMIZE	NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding	1 year	B

RESET	Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke	1 year	B

EXCELLENT	Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding	1 year	B

PEGASUS	Death, MI, stroke, TIMI major and minor bleeding	3 years	B

DAPT	ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5	12 to 30 months	B

Sardella2011	Death, MI, stroke, TIMI minor bleeding, revascularization	2 years	-

PRODIGY	Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding	2 years	B

Thukkani2015	Death, MI, Stroke	4 years	-

ENDEAVOR	Death, MI, ST (definite and probable), stroke, major bleeding	2 years	B

ITALIC	Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding	1 year	B

Studies

Brar2008

I-LOVE IT 2

ISAR-SAFE

Tarantini2016

ARCTIC

OPTIMIZE

RESET

EXCELLENT

PEGASUS

DAPT

Sardella2011

PRODIGY

Thukkani2015

ENDEAVOR

ITALIC

Reported outcomes	Follow up period	Bias grade

Death, MI	9.7 months	-

NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding	12 and 18 months	B

Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding	9 months	B

Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization	1 year	-

Primary endpoints, Death, MI, ST, stroke, revascularization	17 months	B

NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding	1 year	B

Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke	1 year	B

Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding	1 year	B

Death, MI, stroke, TIMI major and minor bleeding	3 years	B

ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5	12 to 30 months	B

Death, MI, stroke, TIMI minor bleeding, revascularization	2 years	-

Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding	2 years	B

Death, MI, Stroke	4 years	-

Death, MI, ST (definite and probable), stroke, major bleeding	2 years	B

Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding	1 year	B


Variable	Univariate	Multivariate	Covariate height	Covariate gender


	User-initiated (n = 17)	Not user-initiated (n = 3)

User investigator	14	–

External user involved since formulation	2	1

External user involved only in interpretation	1	2


Markers	Staining intensity

LNCaP	Spheres	Neuroendocrine cells

Pancytokeratin	+/−	-	+++

Neuro-specific enolase	+/−	−	+++

Serotonin	−	−	+

Markers	Staining intensity

LNCaP

Pancytokeratin	+/−

Neuro-specific enolase	+/−

Serotonin	−

Staining intensity

Spheres	Neuroendocrine cells

-	+++

−	+++

−	+


	certified CAM	noncertified CAM	COM

	mean	median	mean	median	mean	median

Number of patients per year	652	537	955	899	987	906

Number of consultations per year	2797	2440	3811	3726	3918	3783

- Disease related	2746	2421	3694	3621	3822	3731

- Accident related	40	14	100	76	82	46

- Other (maternity, unclassified)	12	2	17	3	13	2

- Number of home visits	79	30	268	181	304	211

Number of consultations per patient and year	4.6	4.2	4.1	3.9	4.2	4.0

	certified CAM	noncertified CAM	COM

	mean	median	mean	median	mean	median

Number of consultations per patient and year	4.6	4.2	4.1	3.9	4.2	4.0


	EEG normal patients = 53(%)	EEG abnormal patients = 17(%)

palpitations, pounding heart, or accelerated heart rate	44 (83.0)	13 (76.5)

sweating	11 (20.8)	5 (29.4)

trembling or shaking	16 (30.2)	5 (29.4)

sensations of shortness of breath or smothering	40 (75.5)	13 (76.5)

feeling of choking	13 (24.5)	4 (23.5)

chest pain or discomfort	22 (41.5)	7 (41.2)

nausea or abdominal distress	20 (37.7)	14 (82.4)

feeling dizzy, unsteady, lightheaded, or faint	38 (71.7)	15 (88.2)

derealization or depersonalization	4 (7.5)	8 (47.1)

fear of losing control or going crazy	23 (43.4)	11 (64.7)

fear of dying	16 (30.2)	5 (29.4)

paresthesias	23 (43.4)	11 (64.7)

chills or hot flushes	11 (20.8)	7 (41.2)

age	34.6 ± 9.3	33.9 ± 9.8

sex	M:17F:36	M: 3F:14

	EEG normal patients = 53(%)	EEG abnormal patients = 17(%)

sex	M:17F:36	M: 3F:14


Costs per patient in different situation in CHF	CMR strategy	“hypothetical” CXA strategy

All tests performed as outpatient procedures in Switzerland	1,984	2,580

CXA performed as an inpatient procedure in Switzerland	2,408	4,638

Costs per patient in different situation in CHF

All tests performed as outpatient procedures in Switzerland

CXA performed as an inpatient procedure in Switzerland

CMR strategy	“hypothetical” CXA strategy

1,984	2,580

2,408	4,638


Sensor	Targeted Gases	Smell Description

TGS 880	volatile vapors from food	food (while cooking)

TGS 825	hydrogen sulfide	rotten egg, sulfurous smells

TGS 826	ammonia	old rotten urine and fish (sharp, penetrating, and irritating smell)

TGS 822	alcohol, xylene, toluene, other VOC	aromatic solvents, wood fermentation, alcoholic beverages

TGS 2610	general hydrocarbons	smell of ripening fruits

TGS 2602	ammonia, hydrogen sulfide,ethanol, toluene	a wide range of smell: from rotten fish to wood fermentattion


Variables	B	SE	Sig.	AOR	95.0 % C.I. for Exp (B)


 	PinX1

Positive	Negative	P

Sex

Male	34	74

Female	7	43	0.020

Age

<60 years	19	52

≥60 years	22	65	0.834

Smoking status

Yes	34	76

No	7	41	0.034

Histology

Squamous	36	65

Adenocarcinoma	5	52	0.000

Lesion

Peripheral	28	83

Central	13	34	0.750

Tumour location

Left	17	48

Right	24	69	0.961

Resection type

Lobectomy	35	95

Pneumonectomy	3	19

Other	3	3	0.163

Metastasis

Yes	15	67

No	26	50	0.023

T stage

T1	6	41

T2 + T3	35	76	0.013

N stage

N0	46	24

N1 + N2	17	71	0.033

TNM stage

I	13	31

II	17	32

III	11	54	0.082


Toxicity	Grade

	0	1	2	3	4	≥Grade 3 (%)

Leukopenia	26	16	17	3	0	5

Neutropenia	32	14	11	5	0	8

Anemia	28	31	3	0	0	0

Thrombocytopenia	33	27	2	0	0	0

Mucositis	1	15	45	1	0	2

Dermatitis	1	58	2	1	0	2

Hoarseness	45	12	4	1	0	2


Groups	Number of patients	Age, y (Mean ± SD)


ital-based case-control studies

[15]	All women	Per 2 years↑	2 years' increase	0.83 (0.68–1.01)	1.11 (0.91–1.36)

16	All women	3	≥14/<12	1.0 (0.53–-2.00)	1.43 (0.71–2.50)

Summary RRs for hospital-based case-control studies	0.84 (0.64–1.10)	1.14 (0.87–1.49)

Summary RRs by MP status	Pre-MP/Young			0.71 (0.57–0.88)	0.77 (0.62–0.95)

	Post-MP			0.74 (0.54–1.01)	0.95 (0.70–1.30)

Summary RRs for all studies	0.72 (0.64–0.80)	0.84 (0.75–0.94)

P for homogeneity between ER+PR+ and ER-PR- cancer	p = 0.006


Test substance	Tomato extract in squalane	Tomato extract in hydrogenated polydecene	Dunaliella extract in hydrogenated polydecene

Reactions noted	None	None	None

# reactive subjects (%)	0 (0%)	0 (0%)	0 (0%)

MDIS	0	0	0

Conclusion	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant

Test substance	Tomato extract in squalane	Tomato extract in hydrogenated polydecene	Dunaliella extract in hydrogenated polydecene

Conclusion	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant


Antibiotic	Proportion susceptible (%)

 	MSSA (n = 80)	MRSA (n = 6)

Cefoxitin	100	0

Benzylpenicillin	26	0

Co-trimoxazole	60	0

Tetracycline	85	0

Gentamicin	99	0

Ciprofloxacin	100	0

Erythromicin/Clindamycin	99	17

Rifampicin	99	83

Chloramphenicol	100	100

Vancomycin	100	100

Mupirocin	100	100


Polymer Type	LOD	Response Time/Recovery Time	Transducing Mechanism	Ref.

PPy nanoparticles	5 ppm	Less than 1 s/2 s	Chemiresistive	[58]

Multidimensional PPy nanotubes	0.01 ppm	Less than 1 s/55–60 s	Chemiresistive	[113]

Single PPy nanowire	40 ppm	15–10 min (for 40–300 ppm)/15 min for 40 ppm	Chemiresistive	[36]

PPy nanowires	1.5 ppm	60 s for 73 ppm/prolonged with increasing of con. (1.5–73 ppm)	Chemiresistive	[18]

Single crystal PPy nanotube	0.00005 ppm	~16 s/~16 s for 1 ppm	Chemiresistive	[114]

PPy nanoribbons	0.5 ppm	~8 min/3 min	Chemiresistive	[62]

PPy nanotubes PPy/Ag–AgCl composite Nanotubes	–	>1000 s for 100 ppm/−150 s for 100 ppm/500 s	Chemiresistive	[115]

PPy/ZnO nanocomposite PPy/SnO2 nanocomposite	10 ppm	~100 s for 24 ppm/100 s ~50 s for 24 ppm/250 s for first 3 cycles	Chemiresistive	[13]

PPy/graphene nanocomposite decorated with TiO2 nanoparticles	1 ppm	~36 s/~16 s for 50 ppm	Chemiresistive	[116]

Au/PPy nanopeapods	0.007 ppmv	~15 min for 5 ppmv/did not reach Ro value	Chemiresistive	[117]


Variable	HIV-1-seronegative psoriasis	HIV-1-related psoriasis	References

Frequency	1-3%	Similar to HIV-seronegative population	[54,55]

Severity	Mild-moderate	Moderate-severe	[62]

Clinical features	Erythematous plaques usually circumscribed to elbows-knees (psoriasis vulgaris)	More extensive lesionsIncreased presence of acral lesions and inverse psoriasis	[4,55]

Histhopatological features	Hyperproliferation and hyperkeratosis, lymphocytic infiltrate and absence of granular layer	Same	[55]

Presence of psoriatic arthritis	5-20%	23%-50%	[54,55]

Mean age of presentation	>30 years	=30 years	[63]

Family history	Frequent	Variable	[64]

Presence of HLA-Cw*0602	25%	79%	[64]

Presence of Reiter's Syndrome	Rare	Frequent	[54]

Development of erythroderma	+/+++	++/+++	[65]

Response to conventional treatment (topical steroids, Vitamin D analogues, phototherapy)	Variable	Variable-poor	[63,66]

Response to zidovudine/HAART	+/+++	++/+++	[67,68]


Group	Hoffman cluster	Species, subspecies, or complex	Type strain	Accession no.	No. of strains

A	VI	E. xiangfangensis	LMG 27195a	NZ_CP017183.1	3

B	VIII	E. hormaechei subsp. steigerwaltii	DSM 16691a	NZ_CP017179.1	83

C	VI	E. hormaechei subsp. oharae	DSM 16687a	NZ_CP017180.1	104

D	III	E. hormaechei	DSM 14563a	NZ_CP017186.1	30

E	VII	E. hormaechei subsp. hormaechei	ATCC 49162	GCA_000213995.1	5

F		E. mori	LMG 25706	AEXB00000000	1

G	XI	E. cloacae subsp. cloacae	ATCC 13047	NC_014121.1	11

H	XII	E. cloacae subsp. dissolvens			4

I	V	E. ludwigii	EN-119	CP017279.1	11

J	I	E. asburiae	ATCC 35953	NZ_CP011863.1	30

K		E. cloacae complex			6

L		E. cloacae complex			7

M	IV	E. cloacae complex	DSM 16690a	NZ_CP017184.1	31

N		E. cloacae complex			3

O		E. cloacae complex			1

P		E. cloacae complex			4

Q	II	E. kobei	DSM 13645a	NZ_CP017181.1	31

R	IX	E. cloacae complex			14

Group

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

Hoffman cluster	Species, subspecies, or complex	Type strain	Accession no.	No. of strains

VI	E. xiangfangensis	LMG 27195a	NZ_CP017183.1	3

VIII	E. hormaechei subsp. steigerwaltii	DSM 16691a	NZ_CP017179.1	83

VI	E. hormaechei subsp. oharae	DSM 16687a	NZ_CP017180.1	104

III	E. hormaechei	DSM 14563a	NZ_CP017186.1	30

VII	E. hormaechei subsp. hormaechei	ATCC 49162	GCA_000213995.1	5

	E. mori	LMG 25706	AEXB00000000	1

XI	E. cloacae subsp. cloacae	ATCC 13047	NC_014121.1	11

XII	E. cloacae subsp. dissolvens			4

V	E. ludwigii	EN-119	CP017279.1	11

I	E. asburiae	ATCC 35953	NZ_CP011863.1	30

	E. cloacae complex			6

	E. cloacae complex			7

IV	E. cloacae complex	DSM 16690a	NZ_CP017184.1	31

	E. cloacae complex			3

	E. cloacae complex			1

	E. cloacae complex			4

II	E. kobei	DSM 13645a	NZ_CP017181.1	31

IX	E. cloacae complex			14


Age					<0.0001

<20	520	0.83	42,313	2.91

20–29	21,471	34.10	706,688	48.66

30–39	35,922	57.06	656,693	45.21

≥40	5045	8.01	46,735	3.22

Obesity	8122	12.90	56,142	3.87	<0.0001

Subsequent diabetes	1266	2.01	1674	0.12	<0.0001

Hypertensive disorders during pregnancy	4834	7.68	42,012	2.89	<0.0001

Angina pectoris	64	0.10	570	0.04	<0.0001

Myocardial infarction

Acute myocardial infarction	26	0.04	257	0.02	<0.0001

Repeated myocardial infarction	0	0	2	0	1

Complications of acute myocardial infarction	0	0	11	0	1

Stroke

Ischemic stroke	71	0.11	1181	0.09	<0.05

Vascular syndromes of brain in cerebrovascular diseases	9	0.01	160	0.01	0.34

Transient cerebral ischemic attacks	59	0.09	1219	0.08	0.06

Hypertensives diseases	1566	2.49	10,586	0.73	<.0001

Therapeutic measuresa	32	0.05	236	0.02	<.0001


Variables	Patients number	%

Age (mean ± SD) days	6.7 ± 2.3

Body weight (mean ± SD) kg	3.4 ± 0.3

Gender

 Male	13	68.4

 Female	6	31.6

Diagnosis

 TGA with VSD	2	10.5

 Taussig–Bing	17	89.5

Arch anomaly

 Coarctation of aorta	13	68.4

 Interruption	6	31.6

 Type A	2	10.5

 Type B	4	21.1

Coronary artery pattern

 1L,Cx; 2R	8	42.1

 1L; 2Cx,R	2 (1RP)	10.5

 1R; 2L,Cx	3 (2RP)	15.8

 1R,L; 2Cx	1 (RP)	5.3

 2L,Cx,R	1 (IM)	5.3

 2L,Cx; 2R	3 (1RP, 1IM)	15.8

 2R; 2L,Cx	1 (RP)	5.3

Relation of gas

 Anteroposterior	4	21.1

 Side by side	15	78.9

PGE1	19	100

Mechanical ventilation	3	15.8

Variables	Patients number	%

Age (mean ± SD) days	6.7 ± 2.3

Body weight (mean ± SD) kg	3.4 ± 0.3

Gender

Male	13	68.4

Female	6	31.6

Diagnosis

TGA with VSD	2	10.5

Taussig–Bing	17	89.5

Arch anomaly

Coarctation of aorta	13	68.4

Interruption	6	31.6

Type A	2	10.5

Type B	4	21.1

Coronary artery pattern

1L,Cx; 2R	8	42.1

1L; 2Cx,R	2 (1RP)	10.5

1R; 2L,Cx	3 (2RP)	15.8

1R,L; 2Cx	1 (RP)	5.3

2L,	1 (	5.3

Variables	Patients number	%

Cx,R	IM)

2L,Cx; 2R	3 (1RP, 1IM)	15.8

2R; 2L,Cx	1 (RP)	5.3

Relation of gas

Anteroposterior	4	21.1

Side by side	15	78.9

PGE1	19	100

Mechanical ventilation	3	15.8


		Odds ratio	95 % confidence intervals

			Lower	Upper

Tobacco	Follow-up vs. Baseline	1.020	0.223	4.661

Nutrition	Follow-up vs. Baseline	1.555	0.814	2.972

Physical activity	Follow-up vs. Baseline	0.946	0.476	1.879

Screening	Follow-up vs. Baseline	2.788*	1.166	6.663

Clinical trials	Follow-up vs. Baseline	3.118*	1.372	7.083

		Odds ratio	95 % confidence intervals

			Lo	Uppe

			wer	r

Tobacco	Follow-up vs. Baseline	1.020	0.223	4.661

Nutrition	Follow-up vs. Baseline	1.555	0.814	2.972

Physical activity	Follow-up vs. Baseline	0.946	0.476	1.879

Screening	Follow-up vs. Baseline	2.788*	1.166	6.663

Clinical trials	Follow-up vs. Baseline	3.118*	1.372	7.083


Diet composition	20% animal protein	10% animal pro+tein	20% plant protein	10% plant protein

Total energy value (kcal/g)	3.7	3.7	3.7	3.7

Carbohydrate (%Kcal)	62.93	73.23	63.15	73.06

Fat (%kcal)	16.97	16.97	16.87	16.74

Protein (%Kcal)	20.11	10.04	19.98	10.20

Leucine (g/kg)	18.7	9.4	21.2	10.6

Isoleucine (g/kg)	10.1	5.0	7.9	4.0

Lysine (g/kg)	15.7	7.9	3.9	1.9

Methionine (g/kg)	4.9	2.4	4.1	2.1

Cysteine (g/kg)	2.0	1.0	3.0	1.5

Arginine (g/kg)	6.7	3.3	7.8	3.9

Phenylalanine (g/kg)	8.8	4.4	10.4	5.2

Tyrosine (g/kg)	9.2	4.6	5.0	2.5

Histidine (g/kg)	4.9	2.4	4.2	2.1

Threonine (g/kg)	8.4	4.2	5.5	2.7

Tryptophan (g/kg)	2.5	1.2	1.6	0.8

Valine (g/kg)	11.8	5.9	8.7	4.3

Wheat gluten (g/kg)	―	―	110	55

Corn gluten (60%) (g/kg)	―	―	136	68

Isolated soy protein (g/kg)	―	―	22	11

Casein (g/kg)	170	85	―	―

Lactalbumin (g/kg)	44	22	―	―

Corn starch (g/kg)	380.1	486.3	325.4	459

Maltodextrin (g/kg)Sucrose (g/kg)	100150	100150	100150	100150

Corn oil (g/kg)	32	32	32	32

Olive oil (g/kg)	32	32	32	32

Cellulose (g/kg)	50	50	50	50

Mineral Mix, w/o Ca & P	13.14	13.14	13.14	13.14

Calcium phosphate (g/kg)	8	10.8	12	12.6

Calcium carbonate (g/kg)	10.3	8.3	7.0	6.8

Vitamin Mix, Tekland (g/kg)	10	10	10	10

Diet composition	20% animal protein	10% animal pro+tein

Total energy value (kcal/g)	3.7	3.7

Carbohydrate (%Kcal)	62.93	73.23

Fat (%kcal)	16.97	16.97

Protein (%Kcal)	20.11	10.04

Leucine (g/kg)	18.7	9.4

Isoleucine (g/kg)	10.1	5.0

Lysine (g/kg)	15.7	7.9

Methionine (g/kg)	4.9	2.4

Cysteine (g/kg)	2.0	1.0

Arginine (g/kg)	6.7	3.3

Phenylalanine (g/kg)	8.8	4.4

Tyrosine (g/kg)	9.2	4.6

Histidine (g/kg)	4.9	2.4

Threonine (g/kg)	8.4	4.2

Tryptophan (g/kg)	2.5	1.2

Valine (g/kg)	11.8	5.9

Wheat gluten (g/kg)	―	―

Corn gluten (60%) (g/kg)	―	―

Isolated soy protein (g/kg)	―	―

Casein (g/kg)	170	85

Lactalbumin (g/kg)	44	22

Corn starch (g/kg)	380.1	486.3

Maltodextrin (g/kg)Sucrose (g/kg)	100150	100150

Corn oil (g/kg)	32	32

Olive oil (g/kg)	32	32

Cellulose (g/kg)	50	50

Mineral Mix, w/o Ca & P	13.14	13.14

Calcium phosphate (g/kg)	8	10.8

Calcium carbonate (g/kg)	10.3	8.3

Vitamin Mix, Tekland (g/kg)	10	10


 	 	<underline>Mean (SD)</underline>

Age	(Year)	43.91 (15.4)

Pain intensity*	(0–10)	4.11 (1.9)

Physical disability**	(0–24)	8.78 (5.3)

Depression***	(0–42)	8.75 (9.9)

Anxiety≠	(0–42)	6.55 (8.4)

Stress±	(0–42)	13.08 (9.8)

Fatigue†	(1–63)	32.49 (12.3)

Pittsburgh questionnaire#	(0 – 21)	7.92 (3.8)

Insomnia index$	(0 – 28)	11.25 (6.4)

Epworth scale¥	(0 – 24)	7.26 (5.2)

Body mass index	(Kg/m2)	25.73 (4.9)

 	 	<underline>N (%)</underline>

Pain duration	Acute	32 (41%)

 	Chronic	47 (59%)

Roland item£	(Yes)	46 (58%)

Seeking care	(Yes)	58 (73%)

Taking pain medication	(Yes)	35 (44%)

Gender	(Female)	40 (51%)

Level of education	(University degree)	35 (44%)

Smoking status	(Not)	74 (94%)

Work status	Full-time	48 (61%)

 	Part-time	14 (18%)

 	Not working	4 (5%)

 	Retired	13 (16%)

Marital status	Married or defacto	39 (49%)

 	Separated	8 (10%)

 	Single	32 (41%)

Age	(Year)

Pain intensity*	(0–10)

Physical disability**	(0–24)

Depression***	(0–42)

Anxiety≠	(0–42)

Stress±	(0–42)

Fatigue†	(1–63)

Pittsburgh questionnaire#	(0 – 21)

Insomnia index$	(0 – 28)

Epworth scale¥	(0 – 24)

Body mass index	(Kg/m2)

Pain duration	Acute

	Chronic

Roland item£	(Yes)

Seeking care	(Yes)

Taking pain medication	(Yes)

Gender	(Female)

Level of education	(University degree)

Smoking status	(Not)

Work status	Full-time

	Part-time

	Not working

	Retired

Marital status	Married or defacto

	Separated

	Single


	Full sample (n = 14,798)	Restricted analytic sample (n = 11,733)

	percent	std error	percent	std error

Age

18–24	17	0.6	18	0.6

26–44	53	0.9	55	1.0

45–64	30	0.8	28	0.9

Gender

Men	49	0.4	49	0.5

Women	51	0.4	51	0.5

Race/ethnicity

White	74	1	75	1

Black	12	0.6	11	0.6

Mexican-American	6	0.5	6	0.5

Other	8	0.9	8	1

Marital status

married/living as	64	0.9	64	0.9

not married/not living as	36	0.9	36	0.9

Education

< high school	23	1	22	1

high school	35	0.8	34	0.8

> high school	42	1	44	1

Occupation

white collar and professional	24	0.9	25	0.9

white collar, semi-routine	23	0.7	23	0.7

blue collar, high skill	12	0.5	12	0.5

blue collar, semi-routine	39	0.8	38	0.9

never worked	3	0.3	3	0.3

Income (equivalized for family size)

< 50% median	22	1	21	1

50–100% median	31	1	30	1

> median	47	2	49	2

% below poverty	11	0.7	11	0.8

% poverty to 184% poverty	16	0.8	15	0.8

185% poverty to median income*	25	1	25	1

> median*	47	2	49	2

Work and health

not currently in labor force	25	0.7	21	0.7

employment affected by health	10	0.4	0	-

death with <1 year follow-up	0.3	0.07	0	-

	Full sample (n = 14,798)	Restricted analytic sample (n = 11,733)

	percent	std error	percent	std error

Race/ethnicity

White	74	1	75	1

Black	12	0.6	11	0.6

Mexican-American	6	0.5	6	0.5

Other	8	0.9	8	1

Marital status

married/living as	64	0.9	64	0.9

not married/not living as	36	0.9	36	0.9

Education

< high school	23	1	22	1

high school	35	0.8	34	0.8

> high school	42	1	44	1

Occupation

white collar and professional	24	0.9	25	0.9

white collar, semi-routine	23	0.7	23	0.7

blue collar, high skill	12	0.5	12	0.5

blue collar, semi-routine	39	0.8	38	0.9

never worked	3	0.3	3	0.3

Income (equivalized for family size)

< 50% median	22	1	21	1

50–100% median	31	1	30	1

> median	47	2	49	2

% below poverty	11	0.7	11	0.8

% poverty to 184% poverty	16	0.8	15	0.8

185% poverty to median income*	25	1	25	1

> median*	47	2	49	2

Work and health

not currently in labor force	25	0.7	21	0.7

employment affected by health	10	0.4	0	-

death with <1 year follow-up	0.3	0.07	0	-


Variable	Number of cases	%

Gender

 Male	116	54

 Female	98	46

Age, y

 < 70	120	56

 ≥ 70	94	44

T-category

 T2	33	15

 T3	181	85

Cancer specific survival, y

 < 5	105	49

 ≥ 5	109	51

 Censored	156	73

Variable	Number of cases

Gender

Male	116

Female	98

Age, y

< 70	120

≥ 70	94

T-category

T2	33

T3	181

Cancer specific survival, y

< 5	105

≥ 5	109

Censored	156


SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS	QUALITY OF LIFE

	Physical	Psychological	Level of independence	Social relationships	Environment	Spirituality/Religion/Personal beliefs

Age*	-0.01	0.04	-0.17†	-0.03	0.10	0.03

Duration of diabetes in years (since first diagnosis)**	-0.02	0.09	-0.17†	-0.02	0.09	0.07

Fasting Glucose mmol/L**	-0.08	-0.15†	-0.00	-0.09	-0.18†	-0.00

HbA1c %*	-0.05	-0.05	-0.00	-0.00	-0.11	0.00

SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS	QUALITY OF LIFE

	Physical	Psychological	Level of independence	Social relationships	Environment	Spirituality/Religion/Personal beliefs

Fasting Glucose mmol/L**	-0.08	-0.15†	-0.00	-0.09	-0.18†	-0.00

HbA1c %*	-0.05	-0.05	-0.00	-0.00	-0.11	0.00


Tissue	Male P Value	Maleρ	Female P-Value	Femaleρ


Disease Duration	Nu	Age (Years, Me	Female 	BMI 	P	RF Pos.	A	Rheumatoid Nodul	Extra-ar	MTX Pre-expo	TNF Pr


HPA	Position	Common allele	Rare allele	Residue variety in β-integrins

1	33	Leu	Pro (Val)	A, D, E, G, K, L, M, N, P, Q, S, T, V, Y

4	143	Arg	Gln	A, E, G, K, N, Q, R, S, T, V

6	489	Arg	Gln	A, D, E, G, H, K, N, P, Q, R, S, T, V

7	407	Pro	Ala	D, E, H, I, K, L, P, Q, R, S, T, V

8	636	Arg	Cys	D, E, G, H, K, L, N, P, Q, R, S, T, Y

10	62	Arg	Gln	D, E, F, H, I, K, L, N, Q, R, S, T, V

11	633	Arg	His	A, D, E, G, H, K, L, N, Q, R, S, T, V

14	611	Lys	del	D, F, H, K, L, N, Q, R, S, Y

16	140	Thr	Ile	A, D, E, G, K, L, N, Q, R, S, T, V


Demographic or Clinical Characteristic	No. of Patients (N= 48)	%

Age, years

 Median		56.6

 Range		29-77

ECOG performance status

 0	19		39.6

 1	23		48

 2	6		12.5

Primary tumor intact	11		23

Skin ulceration	19		40

Lymph node stations clinically involved

 Groin only (stage III)	11		23

 Deep inguinal or pelvic (stage IV)	28		58.3

Distant metastasis	21		43.7

History of smoking	40		83

 Current	6		12.5

 Former	34		70.8

Prior treatment

 Chemotherapy	19		39.6

 Radiation therapy	5		10.4

Presentation of disease

 Primary	17		35.4

 Recurrent	31		64.6


Effects and limitations of management contract	Public sector perspective	private sector perspective

Effects	By introducing competitive forces, contracting puts pressure on both public and private providers in terms of both service and price.	Contracting expands market opportunities to include public sector clients or customers.

Expanding the range of activities subject to contracting encourages the private sector to expand the services it provides in areas desired by government.	Contracting allows a private provider to capture a market to be protected from competitors at least for the term of the contract.

Contracting both requires and promotes better planning and policy development by improving the flow of information about volumes of goods, services, costs, quality, responsiveness, population served, health needs and other issues.	Contracting can provide a reliable and timely source of revenue, encouraging investments necessary to support quality and innovation and ensuring longer term viability.

Contracting provides government with a mechanism for purchasing needed health services at an agreed on and therefore predictable price.	The contract term may provide adequate time to justify investments in the capital and personnel needed to support contractual obligations.

Contracting promotes transparency, constrains conflicts of interest and reduces opportunity for graft and corruption.

Limitations	Qualified private providers may not be available.	The costs of entering the market to compete successfully for government contracts may be too high.

Qualified bidders may not be interested in contracting with government.	The market may be too unstable or the contract period too short to support needed capital investments.

Competition may be weak or non existent.	Transaction costs, the costs of securing and managing the contract may be too high.

Government may discourage bidders by shifting too much risk to providers.	There may be no legal resource if government fails to fulfill its contractual obligations.

Successful contractors could compete with the public sector for health personnel.

Governmental capacity to negotiate contracts may be weak.

Government's managerial and bureaucratic overhead may increase.

Government may agree to disadvantages contract terms.

Long term contracts may restrict government flexibility.

Costs may be higher than anticipated.

Effects and limitations of management contract	Public sector perspective	private sector perspective

Effect	By introducing competitive forces, cont	C

s	racting puts pressure on both public and private providers in terms of both service and price.	ontracting expands market opportunities to include public sector clients or customers.

Expanding the range of activities subject to contracting encourages the private sector to expand the services it provides in areas desired by government.	Contracting allows a private provider to capture a market to be protected from competitors at least for the term of the contract.

Contracting both requires and promotes better planning and policy development by improving the flow of information about volumes of goods, services, costs, quality, responsiveness, population served, health needs and other issues.	Contracting can provide a reliable and timely source of revenue, encouraging investments necessary to support quality and innovation and ensuring longer term viability.

Contracting provides government with a mechanism for purchasing needed health services at an agreed on and therefore predictable price.	The contract term may provide adequate time to justify investments in the capital and personnel needed to support contractual obligations.

Contracting promotes transparency, constrains conflicts of interest and reduces opportunity for graft and corruption.

Limitations	Qualified private providers may not be available.	The costs of entering the market to compete successfully for government contracts may be too high.

Qualified bidders may not be interested in contracting with government.	The market may be too unstable or the contract period too short to support needed capital investments.

Competition may be weak or non existent.	Transaction costs, the costs of securing and managing the contract may be too high.

Government may discourage bidders by shifting too much risk to providers.	There may be no legal resource if government fails to fulfill its contractual obligations.

Successful contractors could compete with the public sector for health personnel.

Governmental capacity to negotiate contracts may be weak.

Government's managerial and bureaucratic overhead may increase.

Government may agree to disadvantages contract terms.

Long term contracts may restrict government flexibility.

Costs may be higher than anticipated.


	No. herds	End of one year study period	Herd size Cow years/year	Calculated bulk tank somatic cell count	Milk production Kg ECM/day	Mastitis treatments % cows treated/cow year	% of cows with infection risk > 50%

Conventional	20	03–2000	83	283	25.7a	74a	42

Organic before 1995	18	03–2000	88	296	22.1c	48b	38

Converting herds before conversion	19	04–1999 or 04–2000	87	317	24.6a,b	61a,b	42

Converting herds first year after conversion	19	04–2000 or 04–2001	101	337	23.3c	52a,b	44

Converting herds second year after conversion	19	04–2001 or 04–2002	107	327	23.8*	48a,b	45

Conventional herds in full research project	109	03–2000	85	309	24.4b	55*	43


History of blood donation	Blood donation total attitude	P value*

score (4–20)

Median	Mean rank

Yes	16.5	196.0	<0.001

No	16	157.2

History of blood donation	Blood donation total attitude

score (4–20)

Median	Mean rank

Yes	16.5	196.0

No	16	157.2


Cumulated Dose (μGy) @ 0.152 m	Cumulated Dose (μGy) @ 0.305 m	Cumulated Dose (μGy) @ 0.914 m


Percentage of 13-to 17-Year-OldGirls Completing HPV Vaccine Series, U.S., 2012

Range	State	Percent	Range	State	Percent

≥50%	Rhode Island	57.7		Kentucky	34.9

	Delaware	50.4		Missouri	34.5

40–49%	Vermont	46.2		New Hampshire	34.5

	Pennsylvania	44.6		Minnesota	33.1

	Hawaii	43.4		Michigan	32.2

	Connecticut	43.6		Ohio	31.9

	Washington	43.5		South Dakota	31.8

	Massachusetts	43		New Jersey	31.6

	Maine	41.8		Alaska	31.4

	Montana	41.6		Alabama	31.1

	North Dakota	40.9		Maryland	30.9

	Louisiana	40.5		New Mexico	30.3

30–39%	New York	39.7		Texas	30.3

	Oregon	38.6		Wyoming	30.3

	District Columbia	38.5	≤29%	Georgia	29

	Oklahoma	38.4		Tennessee	28.6

	Colorado	38		Virginia	27.9

	Wisconsin	37.5		Idaho	27.8

	Nebraska	37.3		South Carolina	26.6

	Nevada	37.2		Florida	25.3

	Arizona	36.9		Kansas	25.1

	West Virginia	36.1		Utah	24.1

	North Carolina	35.5		Illinois	21.1

	California	35.8		Arkansas	18.3

	Iowa	35.6		Mississippi	12.1

	Indiana	35.2

Percentage of 13-to 17-Year-OldGirls Completing HPV Vaccine Series, U.S., 2012

Range	State	Percent	Range	State	Percent

	Wisconsin	37.5		Idaho	27.8

	Nebraska	37.3		South Carolina	26.6

	Nevada	37.2		Florida	25.3

	Arizona	36.9		Kansas	25.1

	West Virginia	36.1		Utah	24.1

	North Carolina	35.5		Illinois	21.1

	California	35.8		Arkansas	18.3

	Iowa	35.6		Mississippi	12.1

	Indiana	35.2


Diagnosis	Tumour biopsy	Perilesional skin	Total

 	No. of positive/total (%)	No. of positive/total (%)	No. of positive/total (%)

BCC	31/50 (62)	24/50 (48)	55/100 (55)

SCC	8/9 (89)	6/9 (67)	14/18 (78)

Total	39/59 (66)	30/59 (51)	69/118 (58)

Diagnosis	Tumour biopsy

	No. of positive/total (%)

BCC	31/50 (62)

SCC	8/9 (89)

Total	39/59 (66)


Approach	Number of Links

2	3	4	5	6	7	8	9	10	All

ELM		2.2			2.56		2.70		3.5	2.


PAH	TEF	Surgeon	 	AT

PAHGas	PAHParticle	PAHGas	PAHParticle

Naphthalene	0.001	1055	1.6	584	1.1

Acenaphthylene	0.001	5.8	ND	3.5	ND

Acenaphthene	0.001	19.9	ND	14.6	ND

Fluorene	0.001	55.4	0.8	42.2	0.5

Phenanthrene	0.001	84.3	3.2	68.3	2.2

Anthracene	0.01	22.2	5.6	16.7	4.0

Fluoranthene	0.001	18.9	3.8	14.2	2.7

Pyrene	0.001	17.8	5.4	13.3	4.1

Benzo[a]anthracene	0.1	ND	2.7	ND	1.3

Chrysene	0.01	ND	3.0	ND	1.4

Benzo[b]fluoranthene	0.1	ND	2.6	ND	1.3

Benzo[k]fluoranthene	0.1	ND	1.5	ND	0.7

BaP	1	ND	1.7	ND	1.1

Indeno[cd]pyrene	0.1	ND	1.8	ND	1.0

Dibenzo[ah]anthracene	5	ND	1.8	ND	1.1

Benzo[ghi]peryrene	0.01	ND	2.1	ND	1.5

BaPeq	1.5	11.4	0.9	7.2

Calculated lifetime cancer risk (×10-6) based on 24-hr exposurea	131	992	78	626

Risk of unit-hour exposure (×10-6)	46.8	29.3

Average operation time (hour/day)	2.5	9.2

Estimated lifetime cancer risk (×10-6)	117	270

PAH	TEF	Surgeon		AT

PAHGas	PAHParticle	PAHGas	PAHParticle

Anthracene	0.01	22.2	5.6	16.7	4.0

Fluoranthene	0.001	18.9	3.8	14.2	2.7

Pyrene	0.001	17.8	5.4	13.3	4.1

Benzo[a]anthracene	0.1	ND	2.7	ND	1.3

Chrysene	0.01	ND	3.0	ND	1.4

Benzo[b]fluoranthene	0.1	ND	2.6	ND	1.3

Benzo[k]fluoranthene	0.1	ND	1.5	ND	0.7

BaP	1	ND	1.7	ND	1.1

Indeno[cd]pyrene	0.1	ND	1.8	ND	1.0

Dibenzo[ah]anthracene	5	ND	1.8	ND	1.1

Benzo[ghi]peryrene	0.01	ND	2.1	ND	1.5

BaPeq	1.5	11.4	0.9	7.2

Calculated lifetime cancer risk (×10-6) based on 24-hr exposurea	131	992	78	626

Risk of unit-hour exposure (×10-6)	46.8	29.3

Average operation time (hour/day)	2.5	9.2

Estimated lifetime cancer risk (×10-6)	117	270


Variable	Category	Fresh samples n (%)	Paraffin-embedded samples n (%)

Non-metastatic	Metastatic

Age	< 50 year	5 (50)	2 (20)	8 (15.4)

	≥ 50 year	5 (50)	8 (80)	44 (84.6)

Gender	Male	7 (70)	10 (100)	31 (59.6)

	Female	3 (30)	0	21 (40.4)


Enrichment Categories	p-Value	FDR	Related Genes

GO processes

Negative regulation of eicosanoid secretion	7.5 × 10−9	3.0 × 10−6	Hrh2, F2rl2

Glucocorticoid biosynthetic process	1.6 × 10−8	3.8 × 10−6	Cacna1h, Hsd3b1

Negative regulation of fatty acid transport	4.1 × 10−8	7.6 × 10−6	Hrh2, F2rl2

System process	4.5 × 10−7	4.5 × 10−5	Actc1, Lmod3, Cacng1, Des, Dcdc2, Tnni2, Hrh2, Myog, Cacna1h, Lmod2, F2rl2, Mb, Rasl10b, Olr1714

Response to hormone	1.1 × 10−6	8.5 × 10−5	Actc1, Lyn, Slco1b2 Dmbt1, Hsd3b1, Myog, Cacna1h, Hrh2, Myb, F2rl2

Cellular component morphogenesis	1.2 × 10−6	8.9 × 10−5	Actc1, Cacna1h, Hrh2, F2rl2, Lyn, Dcdc2, Lmod2, Lmod3, Ntn1

Regulation of neurotransmitter secretion	2.5 × 10−6	1.5 × 10−4	Cacna1h, Cacng1, Hrh2

Calcium ion transmembrane transport	3.6 × 10−6	2.0 × 10−4	Cacna1h, Cacng1, Hrh2

Positive regulation of gamma-aminobutyric acid secretion	3.9 × 10−6	2.1 × 10−4	Hrh2, F2rl2

Calcium ion transport	5.1 × 10−6	2.5 × 10−4	Cacna1h, Cacng1, F2rl2, Hrh2

Diseases (in biomarkers)

Autistic disorder	1.5 × 10−5	8.9 × 10−4	Cacna1h, Hrh2, F2rl2

Child development disorders, pervasive	1.6 × 10−5	9.0 × 10−4	Cacna1h, Hrh2, F2rl2

Communication disorders	6.1 × 10−5	2.3 × 10−3	Dcdc2, Hrh2

Language disorders	6.1 × 10−5	2.3 × 10−3	Dcdc2, Hrh2

Mental disorders diagnosed in childhood	8.8 × 10−5	3.0 × 10−3	Cacna1h, Dcdc2, Hrh2

Tourette syndrome	1.3 × 10−4	4.1 × 10−3	Hrh2, F2rl2

Tic disorders	1.3 × 10−4	4.2 × 10−3	Hrh2, F2rl2

Epilepsy, absence	1.7 × 10−4	4.8 × 10−3	Cacna1h, Cacng1

Neurotoxicity syndromes	2.1 × 10−4	4.8 × 10−3	Hrh2, F2rl2

Pathological conditions, signs and symptoms	5.6 × 10−4	9.1 × 10−3	Des, Dcdc2, Ntn1, Cacng1, Cacna1h, Hsd3b1, Tnni2, F2rl2, Mb, Dmbt1, Actc1, Nags, Napb


Organism	<1 mo	1-11 mos	1-55 yrs	6-12 yrs	> 12 yrs	Age Unk	Total	% of total

Streptococcus pneumoniae	2	31	27	17	87	42	187	37.18

Neisseria species	2	5	14	18	56	12	107	21.27

Haemophilus species	0	18	24	2	9	6	59	11.73

Staphylococcus	0	10	6	2	11	7	36	7.16

Others Gram negative	0	11	2	0	7	2	22	4.39

Escherichia coli	1	2	1	0	15	3	22	4.37

Streptococcus species	 	 	 	 	 	 	19	3.77

Other Gram positives	0	4	3	1	5	0	13	2.6

Enterococcus species	0	3	0	2	1	3	9	1.79

Acinetobacter species	0	4	0	2	2	0	8	1.59

ESBL’s Klebsiella pneumoniae	4	2	0	0	0	1	7	1.39

Klebsiella	0	1	1	0	4	1	7	1.39

Pseudomonas species	0	2	2	1	2	0	7	1.39

Total	9	93	80	45	199	77	503	100.02


Ecological		Levels	Change in change

Model	Dependent variable	PCNSDP	PCDE	HCR	PCNSDP	PCDE	HCR

1	Stunting prevalence	−1.92**	–	–	−0.87	–	–

(0.45)	–	–	(0.69)	–	–

2	Stunting prevalence	–	−5.41**	–	–	1.39	–

–	(0.89)	–	–	(1.47)	–

3	Stunting prevalence	–	–	0.55**	–	–	0.20

–	–	(0.08)	–	–	(0.14)

Ecological		Levels	Change in change

Model	Dependent variable	PCNSDP	PCDE	HCR	PCNSDP	PCDE	HCR

1	Stunting prevalence	(0.45)	–	–	(0.69)	–	–

2	Stunting prevalence	–	−5.41**	–	–	1.39	–

–	(0.89)	–	–	(1.47)	–

3	Stunting prevalence	–	–	0.55**	–	–	0.20

–	–	(0.08)	–	–	(0.14)


ID	Annotation	290 vs. 5532 fold change	290 vs. 5532 – p-value corrected FDR	Normalized expression means 290	Normalized expression means 5532

APOBEC3A	Probable DNA dC- > dU-editing enzyme APOBEC-3A	1.80E+308	0.022	0.000	8.304

BLZF1	Golgin-45	1.80E+308	0.000	0.000	19.258

BTBD11	Ankyrin repeat and BTB/POZ domain-containing protein BTBD11	1.80E+308	0.000	0.000	17.621

CRLF2	Uncharacterized protein	1.80E+308	0.000	0.000	75.314

CSF1	Uncharacterized protein	1.80E+308	0.022	0.000	8.313

CXCL10	C-X-C motif chemokine 10	1.80E+308	0.000	0.000	134.604

CXCL11	C-X-C motif chemokine 11	1.80E+308	0.000	0.000	27.796

DDX58	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58	1.80E+308	0.013	0.000	9.386

DDX60	Probable ATP-dependent RNA helicase DDX60	1.80E+308	0.000	0.000	17.559

DDX60L	Probable ATP-dependent RNA helicase DDX60-like	1.80E+308	0.048	0.000	6.609

EIF2AK2	Interferon-induced, double-stranded RNA-activated protein kinase	1.80E+308	0.006	0.000	11.043

EPSTI1		1.80E+308	0.013	0.000	9.460

GPNMB	Transmembrane glycoprotein NMB	1.80E+308	0.001	0.000	16.139

GYPA	Glycophorin-A	1.80E+308	0.000	0.000	33.703

HERC6	Probable E3 ubiquitin-protein ligase HERC6	1.80E+308	0.030	0.000	7.652

IDO1	Uncharacterized protein	1.80E+308	0.000	0.000	38.529

IFI35	Interferon-induced 35 kDa protein	1.80E+308	0.000	0.000	23.808

IFI44L	Interferon-induced protein 44-like	1.80E+308	0.009	0.000	10.133

IFIT1	Uncharacterized protein	1.80E+308	0.000	0.000	39.978

IFIT3	Interferon-induced protein with tetratricopeptide repeats 3	1.80E+308	0.006	0.000	11.063

IFIT5	Interferon-induced protein with tetratricopeptide repeats 5	1.80E+308	0.001	0.000	14.751

IFITM1	Interferon-induced transmembrane protein 1	1.80E+308	0.000	0.000	41.506

NT5C3	Cytosolic 5′-nucleotidase 3	1.80E+308	0.026	0.000	7.949

PARP9	Uncharacterized protein	1.80E+308	0.032	0.000	7.461

PLSCR1	Phospholipid scramblase 1	1.80E+308	0.002	0.000	13.466

RSAD2	Radical S-adenosyl methionine domain-containing protein 2	1.80E+308	0.003	0.000	12.711

SEPP1	Uncharacterized protein	1.80E+308	0.000	0.000	20.263

SLC39A8	Zinc transporter ZIP8	1.80E+308	0.033	0.000	7.413

SPARC	Uncharacterized protein	1.80E+308	0.013	0.000	9.466

XAF1	XIAP-associated factor 1	1.80E+308	0.003	0.000	12.311

SP110	Uncharacterized protein	6.58E+00	0.000	242.916	1598.704

SAMD9	Uncharacterized protein	–3.18E+00	0.010	27.623	8.683

ADAM19	Uncharacterized protein	–3.18E+00	0.008	29.217	9.184

DSG2	Desmoglein-2	–6.36E+00	0.000	33.496	5.264

SLCO5A1	Uncharacterized protein	–1.27E+01	0.000	47.197	3.709

PGAP1	GPI inositol-deacylase	–1.91E+01	0.000	51.117	2.678

SIGLEC1	Sialoadhesin	–5.09E+01	0.000	112.694	2.214

BRIP1	Fanconi anemia group J protein	–1.80E+308	0.000	23.188	0.000

SGPP2	Sphingosine-1-phosphate phosphatase 2	–1.80E+308	0.000	1262.355	0.000

ID

APOBEC3A

BLZF1

BTBD11

CRLF2

CSF1

CXCL10

CXCL11

DDX58

DDX60

DDX60L

EIF2AK2

EPSTI1

GPNMB

GYPA

HERC6

IDO1

IFI35

IFI44L

IFIT1

IFIT3

IFIT5

IFITM1

NT5C3

PARP9

PLSCR1

RSAD2

SEPP1

SLC39A8

SPARC

XAF1

SP110

SAMD9

ADAM19

DSG2

SLCO5A1

PGAP1

SIGLEC1

BRIP1

SGPP2

Annotation	290 vs. 5532 fold change	290 vs. 5532 – p-value corrected FDR	Normalized expression means 290	Normalized expression means 5532

Probable DNA dC- > dU-editing enzyme APOBEC-3A	1.80E+308	0.022	0.000	8.304

Golgin-45	1.80E+308	0.000	0.000	19.258

Ankyrin repeat and BTB/POZ domain-containing protein BTBD11	1.80E+308	0.000	0.000	17.621

Uncharacterized protein	1.80E+308	0.000	0.000	75.314

Uncharacterized protein	1.80E+308	0.022	0.000	8.313

C-X-C motif chemokine 10	1.80E+308	0.000	0.000	134.604

C-X-C motif chemokine 11	1.80E+308	0.000	0.000	27.796

DEAD (Asp-Glu-Ala-Asp) box polypeptide 58	1.80E+308	0.013	0.000	9.386

Probable ATP-dependent RNA helicase DDX60	1.80E+308	0.000	0.000	17.559

Probable ATP-dependent RNA helicase DDX60-like	1.80E+308	0.048	0.000	6.609

Interferon-induced, double-stranded RNA-activated protein kinase	1.80E+308	0.006	0.000	11.043

	1.80E+308	0.013	0.000	9.460

Transmembrane glycoprotein NMB	1.80E+308	0.001	0.000	16.139

Glycophorin-A	1.80E+308	0.000	0.000	33.703

Probable E3 ubiquitin-protein ligase HERC6	1.80E+308	0.030	0.000	7.652

Uncharacterized protein	1.80E+308	0.000	0.000	38.529

Interferon-induced 35 kDa protein	1.80E+308	0.000	0.000	23.808

Interferon-induced protein 44-like	1.80E+308	0.009	0.000	10.133

Uncharacterized protein	1.80E+308	0.000	0.000	39.978

Interferon-induced protein with tetratricopeptide repeats 3	1.80E+308	0.006	0.000	11.063

Interferon-induced protein with tetratricopeptide repeats 5	1.80E+308	0.001	0.000	14.751

Interferon-induced transmembrane protein 1	1.80E+308	0.000	0.000	41.506

Cytosolic 5′-nucleotidase 3	1.80E+308	0.026	0.000	7.949

Uncharacterized protein	1.80E+308	0.032	0.000	7.461

Phospholipid scramblase 1	1.80E+308	0.002	0.000	13.466

Radical S-adenosyl methionine domain-containing protein 2	1.80E+308	0.003	0.000	12.711

Uncharacterized protein	1.80E+308	0.000	0.000	20.263

Zinc transporter ZIP8	1.80E+308	0.033	0.000	7.413

Uncharacterized protein	1.80E+308	0.013	0.000	9.466

XIAP-associated factor 1	1.80E+308	0.003	0.000	12.311

Uncharacterized protein	6.58E+00	0.000	242.916	1598.704

Uncharacterized protein	–3.18E+00	0.010	27.623	8.683

Uncharacterized protein	–3.18E+00	0.008	29.217	9.184

Desmoglein-2	–6.36E+00	0.000	33.496	5.264

Uncharacterized protein	–1.27E+01	0.000	47.197	3.709

GPI inositol-deacylase	–1.91E+01	0.000	51.117	2.678

Sialoadhesin	–5.09E+01	0.000	112.694	2.214

Fanconi anemia group J protein	–1.80E+308	0.000	23.188	0.000

Sphingosine-1-phosphate phosphatase 2	–1.80E+308	0.000	1262.355	0.000


TRT

Sb1/2e

sb1e

sI1/2e

sI1e

so0e

cb1/2e

cb1e

cI1/2e

cI1e

co0e


Follow-up periods	P value for lab data

	Hemoglobin	TLC	Platelets	Bilirubin	ALT	AST

Before therapy versus after 1 month	0.00	0.78	0.19	0.00	0.00	0.00

After 1 month versus after 3 months	0.285	0.06	0.25	0.00	0.00	0.00

After 3 months versus after 6 months	0.15	0.11	0.35	0.002	0.001	0.00

After 6 months versus after 1 year	0.97	0.16	0.303	0.00	0.013	0.00


Species	GenBank Accession	Reference

Bathymodiolus azoricus	AF334663	[70]

B. thermophilus	AF334664	[70]

Crassostrea virginica 1	AB206328	[58]

Crassostrea virginica 2	AB252064	[57]

Crassostrea virginica 3	AB427186	This paper

Calyptogena sp. SB2001_1	AF334666	[70]

Calyptogena sp. SB2001_2	AF334667	[70]

Crassostrea gigas 1	AB179775	[96]

Crassostrea gigas 2	AB288344	[97]

Crassostrea gigas 3	AB307634	[65]

Crassostrea gigas 4	CU994883	Favrel, direct submission

Chlamys islandica	AJ250028	[52]

Eisenia andrei	DQ339138	Joskova et al. direct submission

Hirudo medicinalis	U24122	[98]

Mytilus edulis 1	AF334662	[70]

Mytilus edulis 2	DQ268868	Caponera and Rawson direct submission

Mytilus galloprovincialis 1	AF334665	[70]

Mytilus galloprovincialis 2	AB298451	Itoh et al. direct submission

Ostrea edulis	AB179776	[96]

Tapes japonica	AB091383	[64]


Day of follow up	0	1	2	3	7	14	21	28

Patients assessed at visit	176	173	172	172	172	171	171	171

Loss to follow up	0	3	1	0	0	1	0	0

Day of follow up	0	1	2	3	7	14	21	28

Patients asses	1	17	17	17	17	17		171

sed at visit	76	3	2	2	2	1	171

Loss to follow up	0	3	1	0	0	1	0	0


Term	MAPP Network Research Definition

Urologic chronic pelvic pain syndrome (UCPPS)	General term to describe idiopathic chronic pelvic pain of urologic origin in men or women. In MAPP Network studies, this includes men and women with IC/BPS, or men with CP/CPPS (see below).

Interstitial cystitis/bladder pain syndrome (IC/BPS)	Chronic unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms, in the absence of infection or other identifiable causes.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)	Chronic idiopathic pelvic pain or discomfort in males, commonly in the perineum, suprapubic region, penis, or testicles, which is often exacerbated by ejaculation or urination.

Non-Urologic Associated Syndromes (NUAS)	General term used to describe symptom-based non-urologic syndromes which co-occur with UCPPS at a rate greater than observed in the general population. Within the MAPP Network, initial efforts have focused on studying specific NUAS (fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome), though other examples exist (e.g. vulvodynia, temperomandibular joint disorder, and migraine headaches, among others).


Name of classifier	MNC	DNC	TNC	IPknot*	IPknot#

BayesNet	0.073	0.084	0.284	-	0.397


Dose	Direction	Striatum	Hippocampus	Cortex

10 mg/kg	Up in YAC128, Down with pridopidine	3.58E-04	3.78E-04	2.40E-04

Down in YAC128, Up with pridopidine	3.64E-04	4.99E-02	2.40E-04

30 mg/kg	Up in YAC128, Down with pridopidine	3.15E-04	3.46E-04	2.35E-04

Down in YAC128, Up with pridopidine	3.37E-04	3.53E-03	2.35E-04

30 mg/kg	Down in YAC128, Up with pridopidine	3.37E-04	3.53E-03	2.35E-04


Saccade Behavior	Leading Vehicle	Speed (km/h)

60	70	80	90	100


Number	Age (years)	Sex	Primary hematological disorder	Organs involved by tuberculosis	Diagnosis of tuberculosis	Treatment/Outcome of tuberculosis

1	55	Male	Chronic myeloid leukemia	Intestine, mesentry and abdominal lymph nodes	Positive lymph node histology and cultures	Given/Successful

2	40	Male	Acute myeloid leukemia	Lungs	Positive sputum cultures	Given/Successful

3	19	Female	Acute myeloid leukemia	Lungs	Positive sputum cultures	Given/Successful

4	20	Female	Hodgkin's lymphoma	Lungs, liver and abdominal lymph nodes	Positive sputum cultures	Given/Successful

5	33	Female	Thrombocytopenic purpura	Cervical lymph nodes	Positive lymph node cultures	Given/Successful

6	70	Male	Hairy cell leukemia	Lungs, liver, spleen, cerebrospinal fluid and bone marrow	Positive cultures(4 sites) and bone marrow histology	Given/Unsuccessful *Multi-drug resistance

7	32	Male	Multiple Myeloma	Lungs	Positive sputum cultures	Given/Successful

8	36	Female	Essential thrombocythemia	Lungs	Positive sputum cultures	Given/Successful

9	24	Male	Acute myeloid leukemia	Lungs, bone marrow and liver.	Positive bronchial lavage	Not given/Death

10	45	Male	Severe aplastic anemia	Lungs	Positive sputum cultures	Not given/Lost follow up

11	70	Male	Myelodysplastic syndrome	Lungs and cervical lymph nodes	Empirical/positive lymph node histology	Given/Successful

12	62	Male	Polycythemia rubra vera	Cervical lymph nodes	Empirical/positive lymph node histology	Given/Successful

13	38	Male	Acute myeloid leukemia	Lungs, bone marrow, psoas muscle and vertebrae.	Empirical/positive muscle and bone marrow histology	Given/Successful

14	52	Female	Chronic myeloid leukemia	Lungs	Empirical/positive serology	Given/Successful

15	59	Male	Myelodysplastic syndrome	Lungs	Empirical/positive serology	Given/Successful

16	75	Male	Myelodysplastic syndrome	Cervical spine	Empirical	Given/Successful

17	60	Female	Myelofibrosis	Lungs	Empirical	Given/Successful

18	65	Male	Chronic myeloid leukemia	Lungs	Empirical	Given/Successful

Number	Age (years)	Sex	Primary hematological disorder	Organs involved by tuberculosis

1	55	Male	Chronic myeloid leukemia	Intestine, mesentry and abdominal lymph nodes

2	40	Male	Acute myeloid leukemia	Lungs

3	19	Female	Acute myeloid leukemia	Lungs

4	20	Female	Hodgkin's lymphoma	Lungs, liver and abdominal lymph nodes

5	33	Female	Thrombocytopenic purpura	Cervical lymph nodes

6	70	Male	Hairy cell leukemia	Lungs, liver, spleen, cerebrospinal fluid and bone marrow

7	32	Male	Multiple Myeloma	Lungs

8	36	Female	Essential thrombocythemia	Lungs

9	24	Male	Acute myeloid leukemia	Lungs, bone marrow and liver.

10	45	Male	Severe aplastic anemia	Lungs

11	70	Male	Myelodysplastic syndrome	Lungs and cervical lymph nodes

12	62	Male	Polycythemia rubra vera	Cervical lymph nodes

13	38	Male	Acute myeloid leukemia	Lungs, bone marrow, psoas muscle and vertebrae.

14	52	Female	Chronic myeloid leukemia	Lungs

15	59	Male	Myelodysplastic syndrome	Lungs

16	75	Male	Myelodysplastic syndrome	Cervical spine

17	60	Female	Myelofibrosis	Lungs

18	65	Male	Chronic myeloid leukemia	Lungs

Diagnosis of tuberculosis	Treatment/Outcome of tuberculosis

Positive lymph node histology and cultures	Given/Successful

Positive sputum cultures	Given/Successful

Positive sputum cultures	Given/Successful

Positive sputum cultures	Given/Successful

Positive lymph node cultures	Given/Successful

Positive cultures(4 sites) and bone marrow histology	Given/Unsuccessful *Multi-drug resistance

Positive sputum cultures	Given/Successful

Positive sputum cultures	Given/Successful

Positive bronchial lavage	Not given/Death

Positive sputum cultures	Not given/Lost follow up

Empirical/positive lymph node histology	Given/Successful

Empirical/positive lymph node histology	Given/Successful

Empirical/positive muscle and bone marrow histology	Given/Successful

Empirical/positive serology	Given/Successful

Empirical/positive serology	Given/Successful

Empirical	Given/Successful

Empirical	Given/Successful

Empirical	Given/Successful


Clinical parameter	AFAP1‐AS1	Chi‐squared test P value

High no. cases	Low no. cases

Age (years)			0.449

≤64	25	12

>64	25	8

Gender			0.451

Male	37	13

Female	13	7

Smoking state			0.880

Yes	24	10

No	26	10

Drinking state			0.508

Yes	41	15

No	9	5

Tumor size			0.040

≤3 cm	14	12

3–5 cm	29	7

>5 cm	7	1

Tumor stage			<0.01

I	2	11

II	27	4

III	21	5

Clinical parameter	AFAP1‐AS1	Chi‐squared test P value

High no. cases	Low no. cases

Age (years)			0.449

≤64	25	12

>64	25	8

Gender			0.451

Male	37	13

Female	13	7

Smoking state			0.880

Yes	24	10

No	26	10

Drinking state			0.508

Yes	41	15

No	9	5

Tumor size			0.040

≤3 cm	14	12

3–5 cm	29	7

>		1

5 cm	7

Tumor stage			<0.01

I	2	11

II	27	4

III	21	5